Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A 51-Year-Old Woman With Bipolar Disorder Who Wants to Quit Smoking

A 51-Year-Old Woman With Bipolar Disorder Who Wants to Quit Smoking Abstract Smoking among patients with mental illness is a major and underappreciated public health problem. The case of Ms G, a 51-year-old woman with bipolar disorder who wishes to quit smoking, illustrates the importance and feasibility of smoking cessation in patients with psychiatric disorders. Persons with chronic mental illness and/or substance abuse constitute 22% of the US population yet are estimated to consume 44% of cigarettes. As many as 200 000 of the 435 000 annual deaths related to smoking in the United States are estimated to occur in this population. On average, patients with mental illness die 25 years earlier than the general population, and smoking is a major contributor to these premature deaths. In the past, mental health clinicians have tended not to address smoking cessation with their patients, but increasing evidence suggests that such reticence is unwarranted, as smoking cessation in this population is feasible. The approach to cessation should include standard interventions of counseling and pharmacotherapy, for which substantial evidence of efficacy exists in patients with and without mental illness. If patients with mental illness are to achieve wellness, smoking cessation must be an integral component of their treatment regimen. DR TESS: Ms G is a 51-year-old woman with a history of bipolar disorder and tobacco use for more than 35 years. She has tried to quit smoking for 8 years and is seeking specialist input as to how to proceed. Ms G began smoking as a teenager. At age 43 years she first attempted to quit using the nicotine patch and hypnosis therapy, but was only able to cut down to 4 cigarettes a day. Since then she has tried other types of nicotine replacement therapy with limited success. She enrolled in group therapy, during which she stopped smoking transiently, but returned to smoking after the sessions ended. Most recently she was prescribed varenicline but was very reluctant to start because of concerns about adverse effects. After discussing the medication with her primary care physician, she began taking it 6 weeks ago. Since then she has been able to again reduce her use to 4 cigarettes a day; however, she believes she is not ready to set a quit date. Ms G was diagnosed as having bipolar disorder at age 36 years. Since then she has had several periods of debilitating depression requiring 4 hospitalizations. Her mood disorder has been treated with lithium and carbamazepine in the past. She is currently maintained on citalopram and risperidone. She finds that periods of unstable mood are the most difficult times to stop smoking. She is currently doing well and reports that her psychiatric symptoms are well controlled. Her medical history is otherwise notable for probable chronic obstructive pulmonary disease, diagnosed on the basis of findings of emphysema on a chest radiograph and recurrent bronchitis. She has had atypical chest pain in the past, with a negative exercise stress test result in 2003. She is postmenopausal and received hormone therapy in the past. Although her bone density scan result was normal 5 years ago, her most recent scan showed evidence of osteopenia. She also has anemia of chronic disease. Her Papanicolaou test and mammogram results have been normal. Her medications include varenicline, 1 mg twice daily; bupropion, 150 mg sustained-release twice daily; gabapentin prescribed for mood stabilization, 400 mg in the morning and 800 mg at night; risperidone, 1 mg at night; and citalopram, 20 mg daily. She has no known drug allergies. Ms G has 3 siblings and graduated from college. She lives alone in elder and disabled housing and has limited social support. She has a remote history of drug use but not intravenous drug use. She has a history of heavy alcohol use but none in more than 20 years. She currently volunteers in the community and is looking for permanent employment. Her father died 1 year ago; her mother is in her 80s and is healthy. Her maternal grandmother and aunt have been diagnosed as having diabetes. There is a history of bipolar disorder in a paternal aunt. Ms g: her view I can't really remember how I started smoking. Somebody offered me a cigarette and I tried it. I really did like it when I started smoking. It's become a way to relax. I first tried to quit in 1999. I was on the patch, and I went to a group for self-hypnosis. It was hard because the woman running the group wanted us to cut down instead of stopping immediately. I knew I could have a cigarette only at certain hours. So in between, I was constantly thinking about having a cigarette. I was obsessed with it. Quitting is anxiety-provoking. You feel like you're getting your arm cut off, like you're going to miss that whole part. That's another thing I don't like about cigarettes. They have that control over you. The second time I tried to quit, I went through an educational program at a hospital that was really helpful. I had a one-on-one person I saw once a week. I was also doing it with other people. When the program ended, I thought, “Oh, I’ll just have 1.” I was having 3 cigarettes a day for a while and then, gradually, more and more. And it was a pack a day again. In 2000, I was doing the patch but then I was smoking while on the patch. And I thought, “I’m going to have a heart attack, so I’d better not do that.” Then I started chewing the gum, but my teeth are not very good, so it was hard to chew. In 2006, I was using the lozenges and feeling pretty good. But I was having fewer cigarettes and more lozenges, so I wasn't really cutting down on the nicotine. I started medication [varenicline] about 2 months ago, and I’ve gradually been cutting down. I don't feel like I want to smoke as much. After the ninth day, you're supposed to quit totally, but I haven't done that. I’ve just been smoking 4 cigarettes a day. I am committed to stopping smoking, but I just keep putting off the day. I’m having trouble setting the date because I guess I’m not full-hearted into quitting. I am wondering if Dr Schroeder thinks I’m going to have to keep taking [varenicline]. I know it's connecting certain things in my brain, but are the connections going to stay that way once I stop taking the medications? At the crossroads: questions for dr schroeder What is the epidemiology of smoking in patients with mental illness in general, in the United States, and elsewhere? What is known about the pathophysiology of smoking and its impact on general health and quality of life in this population? Does smoking cessation exacerbate chronic mental illness? What treatment strategies are available, when are they indicated, and what is the evidence that they are effective in this population? What do you recommend for Ms G? DR SCHROEDER: Ms G, a woman with bipolar disorder who wishes to quit smoking, also represents the larger public health question of smoking cessation in patients with mental illness. Although few trials of smoking cessation in patients with mental illness have been conducted, the serious cardiovascular consequences and increased mortality associated with smoking make smoking cessation essential to incorporate in the treatment of patients with mental illness. Nevertheless, a number of issues specific to treating patients with mental illness have raised clinicians' concerns about smoking cessation. Herein, I examine the evidence that addresses these concerns. Ms G brings many assets to her desire to quit smoking: interest in her health as manifested by attendance at a gym, awareness of the respiratory complications of smoking for her and her family, previous quit attempts, her current low smoking level of only 4 cigarettes per day, the stability of her bipolar disorder, her tolerance of varenicline, which has diminished her cravings for nicotine, and her desire to have smoking cessation counseling. She also faces challenges: a 35-year history of smoking, the complications of her mental illness and its attendant medications, her ambivalence about stopping, and the stigma associated with both smoking and mental illness. What Is the Epidemiology of Smoking in Patients With Mental Illness? Smoking is probably the most common factor contributing to the deaths of persons with mental illness and/or substance abuse disorders, yet this has been a “silent” epidemic.1-3 Rates of smoking are much higher in all categories of mental illness and substance abuse than in the general US population (Table 1).4-11 The US Centers for Disease Control and Prevention currently report a record low smoking prevalence rate of 19.8%11 in the general population, which would be even lower if it excluded persons with mental illness and substance abuse. Despite constituting only 22% of the population, persons with mental illness including substance abuse disorders consume an estimated 44%5 of all cigarettes sold in the United States.12,13 This heavy consumption reflects higher smoking prevalences and the fact that these patients tend to smoke more cigarettes.5,14 Forty-one percent of current smokers report having a mental health diagnosis in the past month and 60% report a mental health diagnosis at some point in their lifetime.12 Among current smokers, the most common mental health diagnoses (reported in the past 30 days) are alcohol abuse, major depressive disorder, anxiety disorders, and illicit drug use or dependence.12 The more severe the psychiatric symptoms, the more likely the patient is to be a smoker.15 These smoking rates take a substantial toll on the population of individuals with mental illness. Although exact numbers are unknown, perhaps as many as 200 000 of the 435 000 annual deaths from smoking in the United States occur among persons with mental illness and/or substance abuse.1,16,17 People with chronic mental illness die, on average, 25 years earlier than the general population,3,17 largely from cardiovascular disease and diabetes mellitus.3 For people with a history of alcohol abuse, such as Ms G, smoking also takes a huge toll. Quiz Ref IDIn a 20-year follow-up study of 845 patients hospitalized for addiction to alcohol or illicit drugs, the observed mortality was 48% vs an expected rate of 18%; half the deaths were attributable to smoking.18 In addition to morbidity and mortality, smoking exerts other tolls: persons with mental illness are more likely to have fixed budgets, and cigarettes may consume more than 25% of the incomes of those receiving public assistance.19,20 Finally, the odor and visual signs of smoking add to the stigma of mental illness, thereby affecting social interaction and job seeking—an activity currently consuming much of Ms G's energy.21-23 In psychiatric hospitals and clinics, cigarettes have historically been used as rewards or punishment, with smoking breaks permitted as a privilege.24-26 Though the practice is waning, it is still in place in some institutions.27 The National Association of State Mental Health Program Directors Research Institute Inc surveyed all state psychiatric hospitals in 2006, with an 82% response rate. Among responding hospitals, 41% reported being nonsmoking and 59% permitted smoking by patients on hospital premises.27 Patient permission to smoke was based on privilege status in the 34% of respondents that permit smoking. Quiz Ref IDThe report further stated that many hospitals responded that gaining access or permission to smoke was a motivator for patients to comply with staff. Family members and staff often viewed smoking as one of the patients' few pleasures and were reluctant to eliminate it. The tobacco industry has been implicated in sponsoring studies that claim that nicotine helps psychiatric symptoms and in opposing smoking bans in institutions.28 The enormity of this disease burden, coupled with the emerging data on the dangers of secondhand smoke, finally galvanized attention about smoking in this population and emphasized the importance of integrating and co-locating psychiatric and medical services, especially smoking cessation.24 The National Association of State Mental Health Program Directors Council has issued a call to action26 and the National Mental Health Partnership for Wellness and Smoking Cessation, a coalition of more than 30 organizations representing mental health clinicians, advocacy, and governmental groups, pledged to promote smoking cessation strategies in settings where mental illness is treated and to change the culture surrounding smoking and mental illness.29 What Is the Pathophysiology of Smoking in This Population? Among the more than 4800 active compounds in tobacco smoke, the addictive component is nicotine. Nicotine stimulates the release of multiple neurotransmitters, including dopamine, norepinephrine, acetylcholine, glutamate, serotonin, β-endorphin, and γ-aminobutyric acid.30,31 Of particular importance for smokers is nicotine's activation of the dopamine reward pathway.30 This pathway—located in the midbrain—is stimulated by crucial biological behaviors that confer species survival value, such as eating when hungry, drinking when thirsty, and engaging in sex.30 Nicotine also helps smokers to concentrate and may help to regulate mood.30 Within seconds after inhaling a cigarette, nicotine enters the brain and stimulates dopamine release and the resultant feeling of pleasure.31 Some authors have considered nicotine addiction a chronic brain disease, and neuroimaging studies of long-term smokers show up-regulation of nicotine receptors in specific brain regions.32,33 In addition, smoking may result in neuroplastic changes that persist for months to years.30 Tobacco use and dependence is highly heritable. Genetically slow metabolism of nicotine may be associated with lower levels of dependence.30 Specific genetic patterns predispose to both depression and nicotine dependence.34-36 Genes that alter dopamine function and transmission may influence the reinforcing effects of smoking, as well as tobacco dependence and the risk of relapse.37 In adolescents, the presence of the DRD2 A1 dopamine receptor allele influences the probability of smoking progression.38 Biological factors also contribute to the high rates of smoking in mental illness, but the “self-medication” hypothesis—that persons with depression smoke to reduce depressive symptoms—has little empirical evidence to support it.39,40 For example, the dopamine release mediated by nicotine may reduce some symptoms in schizophrenia, thereby creating an incentive to smoke.41 Other chemicals in smoke may reduce the symptoms of depression by reducing the monoamine oxidase (MAO) enzymes MAOA and MAOB, similar to the effects of MAO inhibitor antidepressants.30,42 Nicotine also creates a general arousal reaction, which might counter the sedating effects of some psychotropic medications.30Quiz Ref IDHowever, when dependent smokers are deprived of nicotine, they develop withdrawal symptoms, including depression, insomnia, anxiety, irritability, frustration, anger, difficulty concentrating, restlessness, increased appetite, and weight gain.43 Ms G describes these withdrawal symptoms with her prior quit attempts. Because these symptoms mirror those of psychiatric illnesses, especially depression, it is challenging to treat a depressed patient who is trying to stop smoking. Finally, tobacco users on stable regimens of antipsychotic medications and some antidepressants may experience adverse drug events when withdrawing from smoking because of changes in the metabolism of their medication, related to the effects of nicotine on the cytochrome P450 enzyme system.44 For example, smokers have 24% lower levels of phenothiazines, 70% lower levels of haloperidol, and 50% lower levels of caffeine than when they are not smoking.44 When the smoking level is constant, drug metabolism is also constant, but when smoking is either decreasing or increasing, it can result in either unduly high or low medication levels. Does Smoking Cessation Exacerbate Chronic Mental Illness? Some mental health clinicians have traditionally been reluctant to encourage their patients to stop smoking for fear that it will worsen the underlying psychiatric condition. While there is little evidence for this assumption, the association is difficult to disprove.24 The constellation of symptoms that occur during nicotine withdrawal closely parallels those of depression45,46 and the waxing and waning course of mental illness may be difficult to distinguish from the symptoms of withdrawal. Published studies have offered conflicting evidence, with some finding that relapse of depression is related to smoking cessation46-48 and others finding no association.49,50 The tobacco industry has supported some of the studies that concluded that cessation worsens mental health, raising questions about the impartiality of the research.28 One prospective study finding an association between cessation and mental illness controlled for a history of depression and reported a 7-fold increased risk of relapse of depression following smoking cessation, but 39% of the relapsed smokers in the study were lost to follow-up; thus, their depression status could not be confirmed.47 In contrast, a prospective study of 304 smokers in cessation treatment, 32% of whom had a history of depression, found no relation between cigarette abstinence or reduction and depressive episodes after treatment for smoking cessation and concluded that depression recurrence was most strongly predicted by depression history, not by smoking status.49 A randomized trial of 322 actively depressed smokers found no differences in improvement in depression between those who successfully stopped smoking and those who did not and concluded that individuals in treatment for clinical depression can successfully undertake cessation treatment without adverse mental health effects.50 One natural experiment indicates that stopping smoking may not destabilize psychiatric conditions. Quiz Ref IDPsychiatric hospitals17,24,26 are now becoming smoke free, despite initial resistance from staff51—many of whom smoke52—as well as from patients and families24 and from the tobacco industry.28,53 Some staff had warned that removing tobacco privileges would lead to increased violence, disciplinary actions, and exacerbations of psychiatric symptoms. In fact, the opposite occurred, with less violence,26 fewer disciplinary actions,24,52 and more staff contact time with patients in therapeutic settings being reported.24,26 What Is the Evidence That Treatment Strategies Are Effective in This Population? Smoking cessation interventions comprise counseling and pharmacological agents. Tobacco use counseling treatment may be delivered in a variety of formats, including proactive telephone counseling or contact (quit lines and call-back counseling), individual counseling, and group counseling/contact. All forms of intervention increase abstinence rates compared with no intervention.54 A Cochrane review analyzed the effects of smoking cessation programs delivered in a group format compared with self-help materials or with no intervention, compared the effectiveness of group therapy and individual counseling, and determined the effect of adding group therapy to advice from a health care professional or to nicotine replacement. The study also determined whether specific components increased the effectiveness of group therapy. Sixteen studies compared a group program with a self-help program, and cessation increased with the use of a group program (n = 4395; odds ratio [OR], 2.04; 95% confidence interval [CI], 1.60-2.60). Group programs were more effective than no intervention (7 trials; n = 815; OR, 2.17; 95% CI, 1.37-3.45). Group therapy was not more effective than a similar intensity of individual counseling, but the addition of group therapy to other forms of treatment, such as advice from a health care professional or nicotine replacement, appeared to produce extra benefit.55,56 Pharmaceutical interventions include 5 versions of nicotine replacement therapy—a long-acting transdermal patch and 4 shorter-acting formulations (gum, lozenge, nasal spray, and inhaler)—plus 2 drugs that act on the central nervous system, bupropion and varenicline (Table 2).54,57-59 Bupropion is an antidepressant that also reduces cravings for nicotine.60 Varenicline, which was approved by the US Food and Drug Administration (FDA) in 2006 for smoking cessation, is a partial nicotinic cholinergic receptor agonist.58-61 The efficacy of these medications has been extensively reviewed in the Treating Tobacco Use and Dependence: 2008 Update Practice Guideline.54 The update rates the strength of evidence for its recommendations to be level A (“multiple, well-designed randomized clinical trials, directly relevant to the recommendation, yielded a consistent pattern of findings”) for all 7 of these FDA-approved first-line smoking cessation medications. The antidepressant nortriptyline has efficacy similar to bupropion for smoking cessation61 but is seldom used for smoking cessation.54 The efficacy of bupropion and nortriptyline is unrelated to their antidepressant effects. Clonidine is categorized as a second-tier drug but also is seldom used for smoking cessation.54 Selective serotonin reuptake inhibitors, which are commonly prescribed in mental illness, have not been shown to reduce smoking rates.61,62 Opiate antagonists have been tried for smoking cessation, but according to a Cochrane review, there is insufficient evidence to determine whether naltrexone is effective for this indication.63 Multiple trials have documented that counseling alone, medication alone, and the combination of counseling and medication all improve cessation rates compared with placebo.43,54,56 Smoking cessation efficacy rates at 5 months or more after study initiation are as follows. In terms of behavioral interventions, physician advice to quit has an estimated OR of 1.3 (95% CI, 1.1-1.6) compared with no advice to quit, with a percentage abstinence of 10.2% (95% CI, 8.5%-12.0%) vs 7.9%, respectively. Physician counseling provides an OR for abstinence of 2.2 (95% CI, 1.5-3.2), vs 1.7 (95% CI, 1.3-2.1) for counseling by a nonphysician compared with no counseling. Abstinence rates for counseling are 19.9% (95% CI, 13.7%-26.2%), 15.8% (95% CI, 12.8%-18.8%), and 10.2%, respectively. Among types of smoking cessation counseling, individual is most effective (OR, 1.7 [95% CI, 1.4-2.0]; abstinence, 16.8% [95% CI, 14.7%-19.1%]), followed by group (OR, 1.3 [95% CI, 1.1-1.6]; abstinence, 13.9% [95% CI, 11.6%-16.1%]), proactive telephone counseling (OR, 1.2 [95% CI, 1.1-1.4]; abstinence, 13.1% [95% CI, 11.4%-14.8%]), and self-help (OR, 1.2 [95% CI, 1.0-1.3]; abstinence, 12.3% [95% CI, 10.9%-13.6%]), all of which are comparable but all more effective than no intervention (abstinence rate, 10.8%). In terms of pharmacotherapy, the first-line agents (compared with a placebo plus counseling control group, which had an abstinence rate of 13.8%) include varenicline (2 mg/d) (OR of quitting of 3.1 [95% CI, 2.5-3.8]; abstinence, 33.2% [95% CI, 28.9%-37.8%]); bupropion sustained-release (OR, 2.0 [95% CI, 1.8-2.2]; abstinence, 24.2% [95% CI, 22.2%-26.4%]), nicotine nasal spray (OR, 2.3 [95% CI, 1.7-3.0]; abstinence, 26.7% [95% CI, 21.5%-32.7%]); nicotine inhaler (OR, 2.1 [95% CI, 1.5-2.9]; abstinence, 24.8% [95% CI, 19.1%-31.6%]); nicotine lozenge (2 mg) (OR, 2.0 [95% CI, 1.4-2.8]; abstinence, 24.2% [95% CI not reported]); nicotine patch (for 6-14 weeks) (OR, 1.9 [95% CI, 1.7-2.2]; abstinence, 23.4% [95% CI, 21.3%-25.8%]); and nicotine gum (for 6-14 weeks) (OR, 1.5 [95% CI, 1.2-1.7]; abstinence rate, 19.0% [95% CI, 16.5%-21.9%]). Second-line agents (not approved for labeling for this indication by the FDA) include clonidine (OR, 2.1 [95% CI, 1.2-3.7]; abstinence, 25.0% [95% CI, 15.7%-37.3%]) and nortriptyline (OR, 1.8 [95% CI, 1.3-2.6]; abstinence, 22.5% [95% CI, 16.8%-29.4%]). The relative ORs derive from individual studies and do not allow for cross-comparisons of the different pharmacologic agents. Combination therapy includes the nicotine patch (>14 weeks) plus ad lib nicotine (gum or nasal spray), with an OR of 3.6 (95% CI, 2.5-5.2) and an abstinence rate of 36.5% (95% CI, 28.6%-45.3%); nicotine patch plus bupropion sustained-release (OR, 2.5 [95% CI, 1.9-3.4]; abstinence rate, 28.9% [95% CI, 23.5%-35.1%]); nicotine patch plus nortriptyline (OR, 2.3 [95% CI, 1.3-4.2]; abstinence, 27.3% [95% CI, 17.2%-40.4%]); and nicotine patch plus nicotine inhaler (OR, 2.2 [95% CI, 1.2-3.6]; abstinence, 25.8% [95% CI, 17.4%-36.5%]).54,57 Toll-free telephone quit lines—now available for smokers in every state—increase quit rates in a range comparable with drug trials.64-66 Evidence for the efficacy of online quit programs, some but not all of which charge for their services, is also favorable, although less robust than for quit lines.67 Multi-impact systems such as those used by Kaiser Permanente of Northern California have successfully reduced smoking rates in their populations. Using a variety of interventions, including aggressive case-finding plus referral to cessation experts and quit lines, Kaiser was able to reduce its adult smoking prevalence from 12% to 9% in just 3 years.29 Several caveats apply to studies of smoking cessation. First, although smoking changes brain neurotransmitters and neuroplasticity—which should support categorizing it as a chronic disease—the therapies tested in most drug trials stop after 12 weeks.54 In contrast, treatment for other addictions, such as methadone maintenance for heroin addiction, is provided over a much longer duration. It is possible that longer treatment could yield higher cessation rates. For example, 52 weeks of nortriptyline plus extended counseling resulted in 50% cessation rates at the end of treatment.68 Second, smoking is a heterogeneous disease with differing degrees of use and addiction. It may be difficult to generalize results from 1 study to a given patient. Third, the published smoking cessation trials may be unduly optimistic for the average clinic population; quit rates in both the treatment and placebo groups of drug trials are higher than in the general population because of the high motivation of study participants and the higher quality, frequency, and duration of the counseling sessions. Spontaneous unaided quit rates are probably about 4%.54 Also, since the circumstances of each trial are different, one should be wary of making generalizations as to the relative efficacies of the different smoking cessation agents. Finally, drug trials typically exclude patients with mental illness, thereby eliminating a large number of smokers who may have lower cessation rates. Although smoking cessation rates are generally considered to be lower in persons with mental illness and/or substance abuse,48 there is abundant evidence that smokers with mental illness are able to quit. About 70% of smokers with mental illness want to quit,54,69-71 similar to the general population.72Quiz Ref IDFurthermore, a review of 24 published studies for all mental illnesses73 and a meta-analysis of 15 reports on patients with a history of major depression74 both concluded that rates of cessation among these patients were comparable with those of the general population. Specifically for major depression, studies have documented 12-month cessation rates of 22% using the combination of bupropion and counseling75 and as high as 32% for intensive counseling without pharmacotherapy.76 Therefore, clinicians should be encouraged to treat patients with depression and other forms of mental illness, such as Ms G, who want and are able to quit smoking. Unfortunately, clinicians, and physicians in particular, frequently do not incorporate smoking cessation into treatment for their patients with mental health diagnoses.77,78 A 2007 study conducted by the Association of American Medical Colleges/American Legacy Foundation compared physician practice patterns with respect to smoking cessation and found that while 89% of internists and 62% of psychiatrists ask their patients about smoking, only 19% and 14% arrange follow-up and 7% and 2%, respectively, refer patients to quit lines.79 Another study found that 60% of nurses surveyed believed that nicotine was the component in cigarettes that causes cancer and, therefore, were reluctant to recommend nicotine replacement therapy.80 In my experience, other clinicians have similar misunderstandings. What Are the Specific Treatment Concerns in Patients With Mental Illness? Standard cessation treatments of counseling and pharmacotherapy are appropriate in the mentally ill population.54 Bupropion should be considered for smokers with chronic depression, as it could have a double effect. Studies to date have shown higher cessation rates for varenicline plus counseling than for bupropion plus counseling,58,59,81,82 all but 1 of which82 have excluded patients with mental illness. There have been reports of suicidal ideation and worsening psychiatric symptoms in patients taking varenicline, including some who have continued to smoke.83-85 The FDA issued an alert and required Pfizer to provide a warning for varenicline (Chantix) and a change to its label and medication guide to state that “[s]ome patients have reported changes in behavior, agitation, depressed mood, suicidal thoughts or actions when attempting to quit smoking while taking Chantix or after stopping Chantix.” It states that patients experiencing such changes should stop taking Chantix and contact their physician. Of note, bupropion also carries such a warning (http://us.gsk.com/products/assets/us_zyban.pdf). The association between varenicline use and exacerbation of mental illness, the frequency of which has yet to be ascertained, must be balanced against the very high risk of continued smoking. Drug safety trials of varenicline among patients with mental illness are currently recruiting study participants (available at http://www.clinicaltrials.gov by using a search string for varenicline and schizophrenia or mental illness). Arguably, for a patient with acute psychiatric symptoms, cessation attempts should be deferred until they are stabilized,2 although much more research is needed on appropriate timing. Future Directions There are many unanswered questions about timing of cessation attempts for those with mental illness, long-term efficacy of treatments, and harm-reduction strategies that focus on decreasing the number of cigarettes smoked, rather than cessation. Perhaps most importantly, what will it take to command clinicians' attention to the devastating hidden epidemic in this population and undertake cessation efforts to stem it? Answers to these questions will come sooner if the mental health treatment community and the clients and families they represent advocate more strongly in the future than they have in the past. No other issue is as important for the long-term health and well-being of mentally ill patients. For individual patients, the question becomes how can we better motivate the mental health treatment community to give smoking and mental illness a higher priority?86 What is the role of non–mental health clinicians, such as internists and family physicians, in trying to help patients with mental illness stop smoking? As desirable as it might be to transform primary care and all other relevant clinicians—pulmonary specialists, diabetologists, cardiologists, obstetricians—into smoking cessation experts, it is an unrealistic goal. The achievable alternative, and one that I challenge and charge all clinicians with attaining, is to develop systems and resources to marshal essential nicotine cessation services. At a minimum, this should include referring the smoker to a quit line.77 No smoker should leave a physician's office without an offer of help to stop smoking. Recommendations for ms g Ms G should be congratulated for reducing her smoking level to 4 daily cigarettes. Now she should set a date to quit entirely. She is already taking 2 recommended smoking cessation drugs, bupropion and varenicline. There are as yet no studies assessing the efficacy of varenicline in combination with other cessation drugs, although anecdotally, such off-label use is not uncommon. The best cessation results come from a combination of counseling and drugs,54 and Ms G has indicated that she would welcome such counseling. If no counseling services are available at her institution, she should be directed to the free telephone quit line services (1-800-QUIT NOW). This system refers callers to their own state's quit line via this national routing number. Counseling should emphasize the continuing benefits of quitting as well as devise behavioral strategies to combat the urge to smoke. As to her concern about the duration of varenicline treatment, 1 published report has shown better cessation rates from 24-week therapy as opposed to the standard 12 weeks.81 The FDA has approved use of the drug for 6 months for those who initially responded to the drug. Another study of 251 patients randomized to varenicline and 126 to placebo demonstrated that patients can safely use the drug for up to 52 weeks.87 Approximately half of the participants (53.8% in the varenicline group and 46.8% in the placebo group) completed the study. There are no population-based data yet regarding safety or possible adverse effects from longer-term use. Of paramount importance to Ms G and other patients with mental illness is optimal treatment and careful monitoring of her psychotropic medications, as well as caution about symptoms of caffeine excess—both conditions of concern in the setting of decreased tobacco use. Her psychiatrist and internist should also be alert to the serious but rare complications that may be associated with varenicline use: suicidal ideation and mania. Should her current cessation program fail, Ms G should be offered another effort using both short- and longer-acting nicotine replacement therapy—with or without bupropion. Questions and discussion QUESTION: You spoke only briefly about weight gain, but in my practice, that is a tremendous issue for patients who contemplate quitting smoking. Are there any particular strategies for preventing weight gain in this scenario? DR SCHROEDER: Weight gain is a usual consequence of quitting smoking, whether one has mental illness or not, and whether or not cessation therapies are used in the quit attempt.54 The weight gain is said to average about 8 lb but it can be more. Many of the standard psychotropic medications are also associated with weight gain, so this can be an important compounding issue for many people with mental illness. Using bupropion in concert with nicotine replacement therapy, particularly the 4-mg nicotine gum and the lozenges, may delay weight gain, but it still occurs.54,57 It is probably best not to try to get people to change their diet at the same time they are stopping smoking, but once smoking is conquered, weight reduction strategies might be appropriate. It is also worth trying to couple cessation with increased exercise, instituting this in simple steps, such as advising patients to park at the far end of a parking lot instead of the closest spot. QUESTION: The Department of Veterans Affairs (VA) has been very aggressive in trying to reduce the rampant smoking throughout its facilities. Are there data on outcomes in terms of success or failure rates, changes in the costs of caring for the population, and rates of tobacco-associated diseases? DR SCHROEDER: The tobacco industry used to send cigarettes to soldiers in combat. During World War I, General Pershing said, “Send us two things to beat the Germans, bullets and cigarettes.” So we induced young men to smoke. The VA has recently taken on tobacco use as a major issue.88 The VA's facilities actually track cessation efforts as a medical quality indicator and rate their physicians accordingly.89 As a result, the VA does better than most systems in asking about smoking and urging cessation. Smoking cessation rates have not gone down as much as the VA would like, but they are declining.90 And VA facilities are now using telephone quit lines as a successful cessation option.91 Many veterans live at some distance from the local VA, so for them quit lines are a preferred option. I am not aware of whether there have been any documented declines in smoking-related illnesses among veterans as a result of these efforts. MS G’S PRIMARY CARE PHYSICIAN: Ms G is receiving ongoing mental health care. She is seeing a psychiatrist and a social worker regularly. When you refer to her needing “counseling,” do you mean, specifically, counseling directed at smoking cessation? DR SCHROEDER: Psychiatrists and psychiatric social workers are not limited to the typical brief encounter with patients that primary care physicians are. So they have more time to splice in smoking cessation counseling (cognitive and behavioral therapy) along with standard psychotherapy. But they typically don't do it. Why? First, they don't think of it because it is not yet part of the mental health treatment culture. Second, they don't feel comfortable doing it because they lack the training and expertise or, perhaps, because they are smokers themselves. Our center is attempting to make mental health clinicians more knowledgeable about smoking cessation strategies by providing them with a tailored version of the cessation curriculum Rx for Change, prepared by pharmacy faculty at the University of California, San Francisco (UCSF).57 This curriculum demonstrated significant changes in practice behavior of psychiatric residents with respect to undertaking cessation efforts, validated through chart review.92 We will help disseminate that curriculum so counselors will feel more comfortable with cessation efforts. QUESTION: Can you comment on the role of restrictions in public smoking in the decreasing prevalence of tobacco use? DR SCHROEDER: Credit for the decline in smoking prevalence over the past 4 decades generally focuses on a set of policy measures, especially tobacco taxes, clean indoor air laws, countermarketing, and smoking cessation efforts.93 Smoking is becoming denormalized and increasingly stigmatized.22,23 It is disappointing that the prevalence of smoking has plateaued recently, after years of progressive steady decline. But the Centers for Disease Control and Prevention recently reported that smoking prevalence for the first 6 months of 2007 was at a modern age-adjusted low of 19.8%.11 There are tremendous variations in population smoking prevalence. Smoking is much more prevalent in southern states, among the poor, and in people with low educational attainment.77 A recent study showed that patients resume smoking after discharge from mental hospitals but also commented that they were not given adequate cessation assistance.94 QUESTION: If the National Institutes of Health (NIH) is designed to improve the health of Americans and if the biggest preventable problem is tobacco, do you think the NIH ought to change the way it is organized? DR SCHROEDER: The reality today is that the NIH is more concerned with basic mechanisms of disease and molecular biology than in researching the efficacy of various clinical strategies. The latter role tends to be financed by the pharmaceutical industry, but since so many of the evidence-based cessation techniques are either off-patent drugs or counseling, there is little incentive for industry to study these or to analyze the efficacy of various combinations. So, there needs to be pressure on the NIH to expand its research agenda on smoking cessation. But pressures of that sort require well-organized and passionate advocacy groups of patients, families, and clinicians. Because of the stigma surrounding smoking, there are no such advocacy groups. It may be up to the medical and public health community to exert that pressure.1 Back to top Article Information Corresponding Author: Steven A. Schroeder, MD, University of California, San Francisco, 3333 California St, Ste 430, San Francisco, CA 94143-1211 (schroeder@medicine.ucsf.edu). Financial Disclosures: None reported. Funding/Support: Dr Schroeder is funded by the Robert Wood Johnson and American Legacy Foundations. Role of the Sponsor: The funding organizations did not participate in the collection, analysis, and interpretation of the data or in the preparation, review, or approval of the manuscript. Additional Contributions: We thank the patient for sharing her story and for providing permission to publish it. Dr Schroeder is indebted to Erica Solway, MSW, MPH, UCSF, for assistance, to Neal Benowitz, MD, UCSF, and Doug Ziedonis, MD, University of Massachusetts, for comments on an earlier version of the manuscript, to Karen Hudmon, DrPH, PRH, MS, Purdue University, Lisa Kroon, PharmD, CDE, UCSF, and Robin Correlli, PharmD, UCSF, for their superb efforts in creating Rx for Change, and to Amy J. Markowitz, JD, for editorial assistance. Ms Markowitz was compensated for her contributions. This conference took place at the Medicine Grand Rounds at Beth Israel Deaconess Medical Center, Boston, Massachusetts, on December 13, 2007. Clinical Crossroads at Beth Israel Deaconess Medical Center is produced and edited by Risa B. Burns, MD, series editor; Tom Delbanco, MD, Howard Libman, MD, Eileen E. Reynolds, MD, Amy N. Ship, MD, and Anjala V. Tess, MD. References 1. Schroeder SA. A hidden epidemic. Washington Post. November 18, 2007:B07. http://www.washingtonpost.com/wp-dyn/content/article/2007/11/16/AR2007111601618.html. Accessed January 15, 2009 2. Ziedonis DM, Williams JM, Steinberg ML, et al. Addressing tobacco dependence among veterans with a psychiatric disorder: a neglected epidemic of major clinical and public health concern. In: Isaacs SL, Schroeder SA, Simon JA, eds. VA in the Vanguard: Building on Success in Smoking Cessation. Washington, DC: Department of Veterans Affairs; 2005 3. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential lives lost, and causes of death among public health mental clients in eight states. Prev Chronic Dis. 2006;3(2). http://cdc.gov/pcd/issues/2006/Apr/05_0180.htm. Accessed November 1, 2008 4. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76(2-3):135-15715949648PubMedGoogle ScholarCrossref 5. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. JAMA. 2000;284(20):2606-261011086367PubMedGoogle ScholarCrossref 6. Kalman D, Morissette SB, George TP. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict. 2005;14(2):106-12316019961PubMedGoogle ScholarCrossref 7. Kollins SH, McClernon FJ, Fuemmeler BF. Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults. Arch Gen Psychiatry. 2005;62(10):1142-114716203959PubMedGoogle ScholarCrossref 8. Beckham JC, Roodman AA, Shipley RH, et al. Smoking in Vietnam combat veterans with post-traumatic stress disorder. J Trauma Stress. 1995;8(3):461-4727582610PubMedGoogle ScholarCrossref 9. Breslau N, Davis GC, Schultz LR. Posttraumatic stress disorder and the incidence of nicotine, alcohol, and other drug disorders in persons who have experienced trauma. Arch Gen Psychiatry. 2003;60(3):289-29412622662PubMedGoogle ScholarCrossref 10. Grant BF, Hasin DS, Chou SP, Stinson FS, Dawson DA. Nicotine dependence and psychiatric disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61(11):1107-111515520358PubMedGoogle ScholarCrossref 11. National Center for Health Statistics. Early release of selected estimates based on data from the January-June 2007 National Health Interview Study. http://www.cdc.gov/nchs/about/major/nhis/about200712.htm. Accessed November 1, 2008 12. Kandel DB, Huang FY, Davies M. Comorbidity between patterns of substance use dependence and psychiatric syndromes. Drug Alcohol Depend. 2001;64(2):233-24111543993PubMedGoogle ScholarCrossref 13. Satcher DS. Executive summary: a report of the Surgeon General on mental health. Public Health Rep. 2000;115(1):89-10110968589PubMedGoogle ScholarCrossref 14. D’Mello DA, Bandlamudi GR, Colenda CC. Nicotine replacement methods on a psychiatric unit. Am J Drug Alcohol Abuse. 2001;27(3):525-52911506266PubMedGoogle ScholarCrossref 15. Morris CD, Giese AA, Turnbull JJ, Dickinson M, Johnson-Nagel N. Predictors of tobacco use among persons with mental illnesses in a statewide population. Psychiatr Serv. 2006;57(7):1035-103816816291PubMedGoogle ScholarCrossref 16. Williams JM, Ziedonis D. Addressing tobacco among individuals with a mental illness or an addiction. Addict Behav. 2004;29(6):1067-108315236808PubMedGoogle ScholarCrossref 17. Mauer B. Morbidity and mortality in people with serious mental illness. In: Parks J, Svendsen D, Singer P, Foti ME, eds. Technical Report 13. Alexandria, VA: National Association of State Mental Health Program Directors Council; 2006 18. Hurt RD, Offord KP, Croghan IT, et al. Mortality following inpatient addictions treatment: role of tobacco use in a community-based cohort. JAMA. 1996;275(14):1097-11038601929PubMedGoogle ScholarCrossref 19. Steinberg ML, Williams JM, Ziedonis DM. Financial implications of cigarette smoking among individuals with schizophrenia. Tob Control. 2004;13(2):20615175544PubMedGoogle ScholarCrossref 20. Mechanic D, Blider S, McAlpine DD. Employing persons with serious mental illness. Health Aff (Millwood). 2002;21(5):242-25312224889PubMedGoogle ScholarCrossref 21. Chapman S, Freeman B. Markers of the denormalisation of smoking and the tobacco industry. Tob Control. 2008;17(1):25-3118218803PubMedGoogle ScholarCrossref 22. Christakis NA, Fowler JH. The collective dynamics of smoking in a large social network. N Engl J Med. 2008;358(21):2249-225818499567PubMedGoogle ScholarCrossref 23. Schroeder S. Stranded in the periphery-the increasing marginalization of smokers. N Engl J Med. 2008;358(21):2284-228618499574PubMedGoogle ScholarCrossref 24. Williams JM. Eliminating tobacco use in mental health facilities: patients' rights, public health, and policy issues. JAMA. 2008;299(5):571-57318252888PubMedGoogle ScholarCrossref 25. Reilly P, Murphy L, Alderton D. Challenging the smoking culture within a mental health service supportively. Int J Ment Health Nurs. 2006;15(4):272-27817064324PubMedGoogle ScholarCrossref 26. Burke M. Technical report on smoking policy and treatment in state operated psychiatric facilities. In: Parks J, Jewell P, eds. Technical Report 12. Alexandria, VA: National Association of State Mental Health Program Directors Medical Directors Council; 2006 27. Monihan KM, Schacht LM, Parks J. A Comparative Analysis of Smoking Policies and Practices Among State Psychiatric Hospitals. http://www.nri-inc.org/reports_pubs/2006/SmokingPoliciesProceduresReport2006.pdf. Accessed December 11, 2008 28. Prochaska JJ, Hall SM, Bero LA. Tobacco use among individuals with schizophrenia: what role has the tobacco industry played? Schizophr Bull. 2008;34(3):555-56717984298PubMedGoogle ScholarCrossref 29. Smoking Cessation Leadership Center home page. http://smokingcessationleadership.ucsf.edu. Accessed November 2, 2008 30. Benowitz NL. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther. 2008;83(4):531-54118305452PubMedGoogle ScholarCrossref 31. Benowitz NL. Cigarette smoking and nicotine addiction. Med Clin North Am. 1992;76(2):415-4371548969PubMedGoogle Scholar 32. Leshner AI. Drug abuse and addiction are biomedical problems. Hosp Pract. April 1997;2-4Special reportGoogle Scholar 33. Perry DC, Davila-Garcia MI, Stockmeier CA, Kellar KJ. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J Pharmacol Exp Ther. 1999;289(3):1545-155210336551PubMedGoogle Scholar 34. McCaffery JM, Niaura R, Swan GE, Carmelli D. A study of depressive symptoms and smoking behavior in adult male twins from the NHLBI twin study. Nicotine Tob Res. 2003;5(1):77-8312745509PubMedGoogle ScholarCrossref 35. Dierker LC, Avenevoli S, Merikangas KR, Flaherty BP, Stolar M. Association between psychiatric disorders and the progression of tobacco use behaviors. J Am Acad Child Adolesc Psychiatry. 2001;40(10):1159-116711589528PubMedGoogle ScholarCrossref 36. Lyons M, Hitsman B, Xian H, et al. A twin study of smoking, nicotine dependence, and major depression in men. Nicotine Tob Res. 2008;10(1):97-10818188750PubMedGoogle ScholarCrossref 37. Lerman C, Caporaso N, Main D, et al. Depression and self-medication with nicotine: the modifying influence of the dopamine D4 receptor gene. Health Psychol. 1998;17(1):56-629459071PubMedGoogle ScholarCrossref 38. Audrain-McGovern J, Lerman C, Wileyto EP, Rodriguez D, Shields PG. Interacting effects of genetic predisposition and depression on adolescent smoking progression. Am J Psychiatry. 2004;161(7):1224-123015229055PubMedGoogle ScholarCrossref 39. Johnson EO, Breslau N. Is the association of smoking and depression a recent phenomenon? Nicotine Tob Res. 2006;8(2):257-26216766418PubMedGoogle ScholarCrossref 40. Kassel JD, Stroud LR, Paronis CA. Smoking, stress, and negative affect: correlation, causation, and context across stages of smoking. Psychol Bull. 2003;129(2):270-30412696841PubMedGoogle ScholarCrossref 41. Ziedonis DM, Kosten TR, Glazer WM, Frances RJ. Nicotine dependence and schizophrenia. Hosp Community Psychiatry. 1994;45(3):204-2067910577PubMedGoogle Scholar 42. Fowler JS, Volkow ND, Wang GJ, et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature. 1996;379(6567):733-7368602220PubMedGoogle ScholarCrossref 43. Hughes JR. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res. 2007;9(3):315-32717365764PubMedGoogle ScholarCrossref 44. Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm. 2007;64(18):1917-192117823102PubMedGoogle ScholarCrossref 45. Sánchez-Villegas A, Serrano-Martinez M, Alonso A, de Irala J, Tortosa A, Martinez-Gonzalez MA. Role of tobacco use on the incidence of depression in the SUN cohort study. Med Clin (Barc). 2008;130(11):405-40918394364PubMedGoogle ScholarCrossref 46. Paperwalla KN, Levin TT, Weiner J, Saravay SM. Smoking and depression. Med Clin North Am. 2004;88(6):1483-1494, x-xi15464109PubMedGoogle ScholarCrossref 47. Glassman AH, Covey LS, Stetner F, Rivelli S. Smoking cessation and the course of major depression: a follow-up study. Lancet. 2001;357(9272):1929-193211425414PubMedGoogle ScholarCrossref 48. Glassman AH. Cigarette smoking: implications for psychiatric illness. Am J Psychiatry. 1993;150(4):546-5538465868PubMedGoogle Scholar 49. Tsoh JY, Humfleet GL, Munoz RF, Reus VI, Hartz DT, Hall SM. Development of major depression after treatment for smoking cessation. Am J Psychiatry. 2000;157(3):368-37410698811PubMedGoogle ScholarCrossref 50. Prochaska JJ, Hall SM, Tsoh JY, et al. Treating tobacco dependence in clinically depressed smokers: effect of smoking cessation on mental health functioning. Am J Public Health. 2008;98(3):446-44817600251PubMedGoogle ScholarCrossref 51. McNally L, Oyefeso A, Annan J, et al. A survey of staff attitudes to smoking-related policy and intervention in psychiatric and general health care settings. J Public Health (Oxf). 2006;28(3):192-19616809790PubMedGoogle ScholarCrossref 52. Levin A. State hospitals struggle to give up smoking. Psychiatr News. 2007;42:4Google Scholar 53. Apollonio DE, Malone RE. Marketing to the marginalised: tobacco industry targeting of the homeless and mentally ill. Tob Control. 2005;14(6):409-41516319365PubMedGoogle ScholarCrossref 54. Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update Practice Guideline. Rockville, MD: Public Health Service; 2008 55. Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev. 2005;(2):CD00100715846610PubMedGoogle Scholar 56. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2008;(1):CD00014618253970PubMedGoogle Scholar 57. Regents of the University of California, University of Southern California, and Western University of Health Sciences. Rx for Change: Clinician-Assisted Tobacco Cessation. http://rxforchange.ucsf.edu. Accessed November 2, 2008 58. Gonzales D, Rennard SI, Nides M, et al; Varenicline Phase 3 Study Group. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47-5516820546PubMedGoogle ScholarCrossref 59. Jorenby DE, Hays JT, Rigotti NA, et al; Varenicline Phase 3 Study Group. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):56-6316820547PubMedGoogle ScholarCrossref 60. Schroeder SA, Sox HC. Trials that matter: varenicline: a designer drug to help smokers quit. Ann Intern Med. 2006;145(10):784-78517116925PubMedGoogle ScholarCrossref 61. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007;(1):CD00003117253443PubMedGoogle Scholar 62. Killen JD, Fortmann SP, Schatzberg AF, et al. Nicotine patch and paroxetine for smoking cessation. J Consult Clin Psychol. 2000;68(5):883-88911068974PubMedGoogle ScholarCrossref 63. David S, Lancaster T, Stead LF, Evins AE. Opioid antagonists for smoking cessation. Cochrane Database Syst Rev. 2006;(4):CD00308617054160PubMedGoogle Scholar 64. Zhu SH, Anderson CM, Tedeschi GJ, et al. Evidence of real-world effectiveness of a telephone quitline for smokers. N Engl J Med. 2002;347(14):1087-109312362011PubMedGoogle ScholarCrossref 65. Zhu SH, Anderson CM. Tobacco quitlines: where they’ve been and where they're going. In: Isaacs SL, Schroeder SA, Simon JA, eds. VA in the Vanguard: Building Success in Smoking Cessation. Washington, DC: Department of Veterans Affairs; 2005:207-217 66. Ossip-Klein DJ, McIntosh S. Quitlines in North America: evidence base and applications. Am J Med Sci. 2003;326(4):201-20514557735PubMedGoogle ScholarCrossref 67. Muñoz RF, Lenert LL, Delucchi K, et al. Toward evidence-based internet interventions: a Spanish/English Web site for international smoking cessation trials. Nicotine Tob Res. 2006;8(1):77-8716497602PubMedGoogle ScholarCrossref 68. Hall SM, Humfleet GL, Reus VI, Munoz RF, Cullen J. Extended nortriptyline and psychological treatment for cigarette smoking. Am J Psychiatry. 2004;161(11):2100-210715514412PubMedGoogle ScholarCrossref 69. Prochaska JJ, Rossi JS, Redding CA, et al. Depressed smokers and stage of change: implications for treatment interventions. Drug Alcohol Depend. 2004;76(2):143-15115488338PubMedGoogle ScholarCrossref 70. Lucksted A, McGuire C, Postrado L, Kreyenbuhl J, Dixon LB. Specifying cigarette smoking and quitting among people with serious mental illness. Am J Addict. 2004;13(2):128-13815204664PubMedGoogle ScholarCrossref 71. Tsoh JY, Hall SM. Depression and smoking: from the transtheoretical model of change perspective. Addict Behav. 2004;29(4):801-80515135563PubMedGoogle ScholarCrossref 72. Centers for Disease Control and Prevention. Cigarette smoking among adults—United States, 2000. MMWR Morb Mortal Wkly Rep. 2002;51(29):642-64512186222PubMedGoogle Scholar 73. El-Guebaly N, Cathcart J, Currie S, Brown D, Gloster S. Smoking cessation approaches for persons with mental illness or addictive disorders. Psychiatr Serv. 2002;53(9):1166-117012221317PubMedGoogle ScholarCrossref 74. Hitsman B, Borrelli B, McChargue DE, Spring B, Niaura R. History of depression and smoking cessation outcome: a meta-analysis. J Consult Clin Psychol. 2003;71(4):657-66312924670PubMedGoogle ScholarCrossref 75. Brown RA, Niaura R, Lloyd-Richardson EE, et al. Bupropion and cognitive-behavioral treatment for depression in smoking cessation. Nicotine Tob Res. 2007;9(7):721-73017577801PubMedGoogle ScholarCrossref 76. Brown RA, Kahler CW, Niaura R, et al. Cognitive-behavioral treatment for depression in smoking cessation. J Consult Clin Psychol. 2001;69(3):471-48011495176PubMedGoogle ScholarCrossref 77. Schroeder SA. What to do with a patient who smokes. JAMA. 2005;294(4):482-48716046655PubMedGoogle ScholarCrossref 78. Thorndike AN, Stafford RS, Rigotti NA. US physicians' treatment of smoking in outpatients with psychiatric diagnoses. Nicotine Tob Res. 2001;3(1):85-9111260815PubMedGoogle ScholarCrossref 79. American Association of Medical Colleges. Physician Behavior and Practice Patterns Related to Smoking Cessations. http://www.aamc.org/workforce/smoking-cessation-full.pdf. Accessed November 2, 2008 80. Borrelli B, Novak SP. Nurses' knowledge about the risk of light cigarettes and other tobacco “harm reduction” strategies. Nicotine Tob Res. 2007;9(6):653-66117558822PubMedGoogle ScholarCrossref 81. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR.Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):64-7116820548PubMedGoogle ScholarCrossref 82. Stapleton JA, Watson L, Spirling LI, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction. 2008;103(1):146-15418028247PubMedGoogle ScholarCrossref 83. Kohen I, Kremen N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry. 2007;164(8):1269-127017671294PubMedGoogle ScholarCrossref 84. Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry. 2007;164(8):126917671295PubMedGoogle ScholarCrossref 85. Institute for Safe Medication Practices. Strong Safety Signal Seen for New Varenicline Risks. http://www.ismp.org/docs/vareniclinestudy.asp. Accessed November 14, 2008 86. Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA. 2007;298(15):1794-179617940236PubMedGoogle ScholarCrossref 87. Williams KE, Reeves KR, Billing CB Jr, Pennington AM, Gong J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin. 2007;23(4):793-80117407636PubMedGoogle ScholarCrossref 88. Isaacs SL, ed, Schroeder SA, ed, Simon JA, ed. VA in the Vanguard: Building on Success in Smoking Cessation. http://smokingcessationleadership.ucsf.edu/AboutSCLC_vanguard.html. Accessed November 2, 2008 89. Hamlett-Berry K. Smoking cessation policy in the VA health care system: where have we been and where are we going? In: Isaacs SL, Schroeder SA, Simon JA, eds. VA in the Vanguard: Building on Success in Smoking Cessation. Washington, DC: Department of Veterans Affairs; 2005:7-29 90. Saxon AJ. Tobacco use and mental illness: neuropsychiatric links and mechanisms. In: A Preceptor Training Program to Improve Delivery of Tobacco Cessation Treatment for Veterans With Mental Disorders. Washington, DC: Department of Veterans Affairs; 2006:13-14 91. Joseph AM, An LC. Telephone care for smoking cessation in the department of Veterans Affairs. In: Isaacs SL, Schroeder SA, Simon JA, eds. VA in the Vanguard: Building on Success in Smoking Cessation. Washington, DC: Department of Veterans Affairs; 2005:207-217 92. Prochaska JJ, Fromont SC, Leed D, et al. Evaluation of an evidence-based tobacco treatment curriculum for psychiatry residency training programs. Acad PsychiatryIn pressGoogle Scholar 93. Warner KE. Tobacco policy research: insights and contributions to public health policy. In: Warner KE, ed. Tobacco Control Policy. San Francisco, CA: Jossey-Bass; 2007:3-86 94. Prochaska JJ, Fletcher L, Hall SE, Hall SM. Return to smoking following a smoke-free psychiatric hospitalization. Am J Addict. 2006;15(1):15-2216449089PubMedGoogle ScholarCrossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

A 51-Year-Old Woman With Bipolar Disorder Who Wants to Quit Smoking

JAMA , Volume 301 (5) – Feb 4, 2009

Loading next page...
 
/lp/american-medical-association/a-51-year-old-woman-with-bipolar-disorder-who-wants-to-quit-smoking-qQxT5QjY2H

References (142)

Publisher
American Medical Association
Copyright
Copyright © 2009 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.281.16.1531
Publisher site
See Article on Publisher Site

Abstract

Abstract Smoking among patients with mental illness is a major and underappreciated public health problem. The case of Ms G, a 51-year-old woman with bipolar disorder who wishes to quit smoking, illustrates the importance and feasibility of smoking cessation in patients with psychiatric disorders. Persons with chronic mental illness and/or substance abuse constitute 22% of the US population yet are estimated to consume 44% of cigarettes. As many as 200 000 of the 435 000 annual deaths related to smoking in the United States are estimated to occur in this population. On average, patients with mental illness die 25 years earlier than the general population, and smoking is a major contributor to these premature deaths. In the past, mental health clinicians have tended not to address smoking cessation with their patients, but increasing evidence suggests that such reticence is unwarranted, as smoking cessation in this population is feasible. The approach to cessation should include standard interventions of counseling and pharmacotherapy, for which substantial evidence of efficacy exists in patients with and without mental illness. If patients with mental illness are to achieve wellness, smoking cessation must be an integral component of their treatment regimen. DR TESS: Ms G is a 51-year-old woman with a history of bipolar disorder and tobacco use for more than 35 years. She has tried to quit smoking for 8 years and is seeking specialist input as to how to proceed. Ms G began smoking as a teenager. At age 43 years she first attempted to quit using the nicotine patch and hypnosis therapy, but was only able to cut down to 4 cigarettes a day. Since then she has tried other types of nicotine replacement therapy with limited success. She enrolled in group therapy, during which she stopped smoking transiently, but returned to smoking after the sessions ended. Most recently she was prescribed varenicline but was very reluctant to start because of concerns about adverse effects. After discussing the medication with her primary care physician, she began taking it 6 weeks ago. Since then she has been able to again reduce her use to 4 cigarettes a day; however, she believes she is not ready to set a quit date. Ms G was diagnosed as having bipolar disorder at age 36 years. Since then she has had several periods of debilitating depression requiring 4 hospitalizations. Her mood disorder has been treated with lithium and carbamazepine in the past. She is currently maintained on citalopram and risperidone. She finds that periods of unstable mood are the most difficult times to stop smoking. She is currently doing well and reports that her psychiatric symptoms are well controlled. Her medical history is otherwise notable for probable chronic obstructive pulmonary disease, diagnosed on the basis of findings of emphysema on a chest radiograph and recurrent bronchitis. She has had atypical chest pain in the past, with a negative exercise stress test result in 2003. She is postmenopausal and received hormone therapy in the past. Although her bone density scan result was normal 5 years ago, her most recent scan showed evidence of osteopenia. She also has anemia of chronic disease. Her Papanicolaou test and mammogram results have been normal. Her medications include varenicline, 1 mg twice daily; bupropion, 150 mg sustained-release twice daily; gabapentin prescribed for mood stabilization, 400 mg in the morning and 800 mg at night; risperidone, 1 mg at night; and citalopram, 20 mg daily. She has no known drug allergies. Ms G has 3 siblings and graduated from college. She lives alone in elder and disabled housing and has limited social support. She has a remote history of drug use but not intravenous drug use. She has a history of heavy alcohol use but none in more than 20 years. She currently volunteers in the community and is looking for permanent employment. Her father died 1 year ago; her mother is in her 80s and is healthy. Her maternal grandmother and aunt have been diagnosed as having diabetes. There is a history of bipolar disorder in a paternal aunt. Ms g: her view I can't really remember how I started smoking. Somebody offered me a cigarette and I tried it. I really did like it when I started smoking. It's become a way to relax. I first tried to quit in 1999. I was on the patch, and I went to a group for self-hypnosis. It was hard because the woman running the group wanted us to cut down instead of stopping immediately. I knew I could have a cigarette only at certain hours. So in between, I was constantly thinking about having a cigarette. I was obsessed with it. Quitting is anxiety-provoking. You feel like you're getting your arm cut off, like you're going to miss that whole part. That's another thing I don't like about cigarettes. They have that control over you. The second time I tried to quit, I went through an educational program at a hospital that was really helpful. I had a one-on-one person I saw once a week. I was also doing it with other people. When the program ended, I thought, “Oh, I’ll just have 1.” I was having 3 cigarettes a day for a while and then, gradually, more and more. And it was a pack a day again. In 2000, I was doing the patch but then I was smoking while on the patch. And I thought, “I’m going to have a heart attack, so I’d better not do that.” Then I started chewing the gum, but my teeth are not very good, so it was hard to chew. In 2006, I was using the lozenges and feeling pretty good. But I was having fewer cigarettes and more lozenges, so I wasn't really cutting down on the nicotine. I started medication [varenicline] about 2 months ago, and I’ve gradually been cutting down. I don't feel like I want to smoke as much. After the ninth day, you're supposed to quit totally, but I haven't done that. I’ve just been smoking 4 cigarettes a day. I am committed to stopping smoking, but I just keep putting off the day. I’m having trouble setting the date because I guess I’m not full-hearted into quitting. I am wondering if Dr Schroeder thinks I’m going to have to keep taking [varenicline]. I know it's connecting certain things in my brain, but are the connections going to stay that way once I stop taking the medications? At the crossroads: questions for dr schroeder What is the epidemiology of smoking in patients with mental illness in general, in the United States, and elsewhere? What is known about the pathophysiology of smoking and its impact on general health and quality of life in this population? Does smoking cessation exacerbate chronic mental illness? What treatment strategies are available, when are they indicated, and what is the evidence that they are effective in this population? What do you recommend for Ms G? DR SCHROEDER: Ms G, a woman with bipolar disorder who wishes to quit smoking, also represents the larger public health question of smoking cessation in patients with mental illness. Although few trials of smoking cessation in patients with mental illness have been conducted, the serious cardiovascular consequences and increased mortality associated with smoking make smoking cessation essential to incorporate in the treatment of patients with mental illness. Nevertheless, a number of issues specific to treating patients with mental illness have raised clinicians' concerns about smoking cessation. Herein, I examine the evidence that addresses these concerns. Ms G brings many assets to her desire to quit smoking: interest in her health as manifested by attendance at a gym, awareness of the respiratory complications of smoking for her and her family, previous quit attempts, her current low smoking level of only 4 cigarettes per day, the stability of her bipolar disorder, her tolerance of varenicline, which has diminished her cravings for nicotine, and her desire to have smoking cessation counseling. She also faces challenges: a 35-year history of smoking, the complications of her mental illness and its attendant medications, her ambivalence about stopping, and the stigma associated with both smoking and mental illness. What Is the Epidemiology of Smoking in Patients With Mental Illness? Smoking is probably the most common factor contributing to the deaths of persons with mental illness and/or substance abuse disorders, yet this has been a “silent” epidemic.1-3 Rates of smoking are much higher in all categories of mental illness and substance abuse than in the general US population (Table 1).4-11 The US Centers for Disease Control and Prevention currently report a record low smoking prevalence rate of 19.8%11 in the general population, which would be even lower if it excluded persons with mental illness and substance abuse. Despite constituting only 22% of the population, persons with mental illness including substance abuse disorders consume an estimated 44%5 of all cigarettes sold in the United States.12,13 This heavy consumption reflects higher smoking prevalences and the fact that these patients tend to smoke more cigarettes.5,14 Forty-one percent of current smokers report having a mental health diagnosis in the past month and 60% report a mental health diagnosis at some point in their lifetime.12 Among current smokers, the most common mental health diagnoses (reported in the past 30 days) are alcohol abuse, major depressive disorder, anxiety disorders, and illicit drug use or dependence.12 The more severe the psychiatric symptoms, the more likely the patient is to be a smoker.15 These smoking rates take a substantial toll on the population of individuals with mental illness. Although exact numbers are unknown, perhaps as many as 200 000 of the 435 000 annual deaths from smoking in the United States occur among persons with mental illness and/or substance abuse.1,16,17 People with chronic mental illness die, on average, 25 years earlier than the general population,3,17 largely from cardiovascular disease and diabetes mellitus.3 For people with a history of alcohol abuse, such as Ms G, smoking also takes a huge toll. Quiz Ref IDIn a 20-year follow-up study of 845 patients hospitalized for addiction to alcohol or illicit drugs, the observed mortality was 48% vs an expected rate of 18%; half the deaths were attributable to smoking.18 In addition to morbidity and mortality, smoking exerts other tolls: persons with mental illness are more likely to have fixed budgets, and cigarettes may consume more than 25% of the incomes of those receiving public assistance.19,20 Finally, the odor and visual signs of smoking add to the stigma of mental illness, thereby affecting social interaction and job seeking—an activity currently consuming much of Ms G's energy.21-23 In psychiatric hospitals and clinics, cigarettes have historically been used as rewards or punishment, with smoking breaks permitted as a privilege.24-26 Though the practice is waning, it is still in place in some institutions.27 The National Association of State Mental Health Program Directors Research Institute Inc surveyed all state psychiatric hospitals in 2006, with an 82% response rate. Among responding hospitals, 41% reported being nonsmoking and 59% permitted smoking by patients on hospital premises.27 Patient permission to smoke was based on privilege status in the 34% of respondents that permit smoking. Quiz Ref IDThe report further stated that many hospitals responded that gaining access or permission to smoke was a motivator for patients to comply with staff. Family members and staff often viewed smoking as one of the patients' few pleasures and were reluctant to eliminate it. The tobacco industry has been implicated in sponsoring studies that claim that nicotine helps psychiatric symptoms and in opposing smoking bans in institutions.28 The enormity of this disease burden, coupled with the emerging data on the dangers of secondhand smoke, finally galvanized attention about smoking in this population and emphasized the importance of integrating and co-locating psychiatric and medical services, especially smoking cessation.24 The National Association of State Mental Health Program Directors Council has issued a call to action26 and the National Mental Health Partnership for Wellness and Smoking Cessation, a coalition of more than 30 organizations representing mental health clinicians, advocacy, and governmental groups, pledged to promote smoking cessation strategies in settings where mental illness is treated and to change the culture surrounding smoking and mental illness.29 What Is the Pathophysiology of Smoking in This Population? Among the more than 4800 active compounds in tobacco smoke, the addictive component is nicotine. Nicotine stimulates the release of multiple neurotransmitters, including dopamine, norepinephrine, acetylcholine, glutamate, serotonin, β-endorphin, and γ-aminobutyric acid.30,31 Of particular importance for smokers is nicotine's activation of the dopamine reward pathway.30 This pathway—located in the midbrain—is stimulated by crucial biological behaviors that confer species survival value, such as eating when hungry, drinking when thirsty, and engaging in sex.30 Nicotine also helps smokers to concentrate and may help to regulate mood.30 Within seconds after inhaling a cigarette, nicotine enters the brain and stimulates dopamine release and the resultant feeling of pleasure.31 Some authors have considered nicotine addiction a chronic brain disease, and neuroimaging studies of long-term smokers show up-regulation of nicotine receptors in specific brain regions.32,33 In addition, smoking may result in neuroplastic changes that persist for months to years.30 Tobacco use and dependence is highly heritable. Genetically slow metabolism of nicotine may be associated with lower levels of dependence.30 Specific genetic patterns predispose to both depression and nicotine dependence.34-36 Genes that alter dopamine function and transmission may influence the reinforcing effects of smoking, as well as tobacco dependence and the risk of relapse.37 In adolescents, the presence of the DRD2 A1 dopamine receptor allele influences the probability of smoking progression.38 Biological factors also contribute to the high rates of smoking in mental illness, but the “self-medication” hypothesis—that persons with depression smoke to reduce depressive symptoms—has little empirical evidence to support it.39,40 For example, the dopamine release mediated by nicotine may reduce some symptoms in schizophrenia, thereby creating an incentive to smoke.41 Other chemicals in smoke may reduce the symptoms of depression by reducing the monoamine oxidase (MAO) enzymes MAOA and MAOB, similar to the effects of MAO inhibitor antidepressants.30,42 Nicotine also creates a general arousal reaction, which might counter the sedating effects of some psychotropic medications.30Quiz Ref IDHowever, when dependent smokers are deprived of nicotine, they develop withdrawal symptoms, including depression, insomnia, anxiety, irritability, frustration, anger, difficulty concentrating, restlessness, increased appetite, and weight gain.43 Ms G describes these withdrawal symptoms with her prior quit attempts. Because these symptoms mirror those of psychiatric illnesses, especially depression, it is challenging to treat a depressed patient who is trying to stop smoking. Finally, tobacco users on stable regimens of antipsychotic medications and some antidepressants may experience adverse drug events when withdrawing from smoking because of changes in the metabolism of their medication, related to the effects of nicotine on the cytochrome P450 enzyme system.44 For example, smokers have 24% lower levels of phenothiazines, 70% lower levels of haloperidol, and 50% lower levels of caffeine than when they are not smoking.44 When the smoking level is constant, drug metabolism is also constant, but when smoking is either decreasing or increasing, it can result in either unduly high or low medication levels. Does Smoking Cessation Exacerbate Chronic Mental Illness? Some mental health clinicians have traditionally been reluctant to encourage their patients to stop smoking for fear that it will worsen the underlying psychiatric condition. While there is little evidence for this assumption, the association is difficult to disprove.24 The constellation of symptoms that occur during nicotine withdrawal closely parallels those of depression45,46 and the waxing and waning course of mental illness may be difficult to distinguish from the symptoms of withdrawal. Published studies have offered conflicting evidence, with some finding that relapse of depression is related to smoking cessation46-48 and others finding no association.49,50 The tobacco industry has supported some of the studies that concluded that cessation worsens mental health, raising questions about the impartiality of the research.28 One prospective study finding an association between cessation and mental illness controlled for a history of depression and reported a 7-fold increased risk of relapse of depression following smoking cessation, but 39% of the relapsed smokers in the study were lost to follow-up; thus, their depression status could not be confirmed.47 In contrast, a prospective study of 304 smokers in cessation treatment, 32% of whom had a history of depression, found no relation between cigarette abstinence or reduction and depressive episodes after treatment for smoking cessation and concluded that depression recurrence was most strongly predicted by depression history, not by smoking status.49 A randomized trial of 322 actively depressed smokers found no differences in improvement in depression between those who successfully stopped smoking and those who did not and concluded that individuals in treatment for clinical depression can successfully undertake cessation treatment without adverse mental health effects.50 One natural experiment indicates that stopping smoking may not destabilize psychiatric conditions. Quiz Ref IDPsychiatric hospitals17,24,26 are now becoming smoke free, despite initial resistance from staff51—many of whom smoke52—as well as from patients and families24 and from the tobacco industry.28,53 Some staff had warned that removing tobacco privileges would lead to increased violence, disciplinary actions, and exacerbations of psychiatric symptoms. In fact, the opposite occurred, with less violence,26 fewer disciplinary actions,24,52 and more staff contact time with patients in therapeutic settings being reported.24,26 What Is the Evidence That Treatment Strategies Are Effective in This Population? Smoking cessation interventions comprise counseling and pharmacological agents. Tobacco use counseling treatment may be delivered in a variety of formats, including proactive telephone counseling or contact (quit lines and call-back counseling), individual counseling, and group counseling/contact. All forms of intervention increase abstinence rates compared with no intervention.54 A Cochrane review analyzed the effects of smoking cessation programs delivered in a group format compared with self-help materials or with no intervention, compared the effectiveness of group therapy and individual counseling, and determined the effect of adding group therapy to advice from a health care professional or to nicotine replacement. The study also determined whether specific components increased the effectiveness of group therapy. Sixteen studies compared a group program with a self-help program, and cessation increased with the use of a group program (n = 4395; odds ratio [OR], 2.04; 95% confidence interval [CI], 1.60-2.60). Group programs were more effective than no intervention (7 trials; n = 815; OR, 2.17; 95% CI, 1.37-3.45). Group therapy was not more effective than a similar intensity of individual counseling, but the addition of group therapy to other forms of treatment, such as advice from a health care professional or nicotine replacement, appeared to produce extra benefit.55,56 Pharmaceutical interventions include 5 versions of nicotine replacement therapy—a long-acting transdermal patch and 4 shorter-acting formulations (gum, lozenge, nasal spray, and inhaler)—plus 2 drugs that act on the central nervous system, bupropion and varenicline (Table 2).54,57-59 Bupropion is an antidepressant that also reduces cravings for nicotine.60 Varenicline, which was approved by the US Food and Drug Administration (FDA) in 2006 for smoking cessation, is a partial nicotinic cholinergic receptor agonist.58-61 The efficacy of these medications has been extensively reviewed in the Treating Tobacco Use and Dependence: 2008 Update Practice Guideline.54 The update rates the strength of evidence for its recommendations to be level A (“multiple, well-designed randomized clinical trials, directly relevant to the recommendation, yielded a consistent pattern of findings”) for all 7 of these FDA-approved first-line smoking cessation medications. The antidepressant nortriptyline has efficacy similar to bupropion for smoking cessation61 but is seldom used for smoking cessation.54 The efficacy of bupropion and nortriptyline is unrelated to their antidepressant effects. Clonidine is categorized as a second-tier drug but also is seldom used for smoking cessation.54 Selective serotonin reuptake inhibitors, which are commonly prescribed in mental illness, have not been shown to reduce smoking rates.61,62 Opiate antagonists have been tried for smoking cessation, but according to a Cochrane review, there is insufficient evidence to determine whether naltrexone is effective for this indication.63 Multiple trials have documented that counseling alone, medication alone, and the combination of counseling and medication all improve cessation rates compared with placebo.43,54,56 Smoking cessation efficacy rates at 5 months or more after study initiation are as follows. In terms of behavioral interventions, physician advice to quit has an estimated OR of 1.3 (95% CI, 1.1-1.6) compared with no advice to quit, with a percentage abstinence of 10.2% (95% CI, 8.5%-12.0%) vs 7.9%, respectively. Physician counseling provides an OR for abstinence of 2.2 (95% CI, 1.5-3.2), vs 1.7 (95% CI, 1.3-2.1) for counseling by a nonphysician compared with no counseling. Abstinence rates for counseling are 19.9% (95% CI, 13.7%-26.2%), 15.8% (95% CI, 12.8%-18.8%), and 10.2%, respectively. Among types of smoking cessation counseling, individual is most effective (OR, 1.7 [95% CI, 1.4-2.0]; abstinence, 16.8% [95% CI, 14.7%-19.1%]), followed by group (OR, 1.3 [95% CI, 1.1-1.6]; abstinence, 13.9% [95% CI, 11.6%-16.1%]), proactive telephone counseling (OR, 1.2 [95% CI, 1.1-1.4]; abstinence, 13.1% [95% CI, 11.4%-14.8%]), and self-help (OR, 1.2 [95% CI, 1.0-1.3]; abstinence, 12.3% [95% CI, 10.9%-13.6%]), all of which are comparable but all more effective than no intervention (abstinence rate, 10.8%). In terms of pharmacotherapy, the first-line agents (compared with a placebo plus counseling control group, which had an abstinence rate of 13.8%) include varenicline (2 mg/d) (OR of quitting of 3.1 [95% CI, 2.5-3.8]; abstinence, 33.2% [95% CI, 28.9%-37.8%]); bupropion sustained-release (OR, 2.0 [95% CI, 1.8-2.2]; abstinence, 24.2% [95% CI, 22.2%-26.4%]), nicotine nasal spray (OR, 2.3 [95% CI, 1.7-3.0]; abstinence, 26.7% [95% CI, 21.5%-32.7%]); nicotine inhaler (OR, 2.1 [95% CI, 1.5-2.9]; abstinence, 24.8% [95% CI, 19.1%-31.6%]); nicotine lozenge (2 mg) (OR, 2.0 [95% CI, 1.4-2.8]; abstinence, 24.2% [95% CI not reported]); nicotine patch (for 6-14 weeks) (OR, 1.9 [95% CI, 1.7-2.2]; abstinence, 23.4% [95% CI, 21.3%-25.8%]); and nicotine gum (for 6-14 weeks) (OR, 1.5 [95% CI, 1.2-1.7]; abstinence rate, 19.0% [95% CI, 16.5%-21.9%]). Second-line agents (not approved for labeling for this indication by the FDA) include clonidine (OR, 2.1 [95% CI, 1.2-3.7]; abstinence, 25.0% [95% CI, 15.7%-37.3%]) and nortriptyline (OR, 1.8 [95% CI, 1.3-2.6]; abstinence, 22.5% [95% CI, 16.8%-29.4%]). The relative ORs derive from individual studies and do not allow for cross-comparisons of the different pharmacologic agents. Combination therapy includes the nicotine patch (>14 weeks) plus ad lib nicotine (gum or nasal spray), with an OR of 3.6 (95% CI, 2.5-5.2) and an abstinence rate of 36.5% (95% CI, 28.6%-45.3%); nicotine patch plus bupropion sustained-release (OR, 2.5 [95% CI, 1.9-3.4]; abstinence rate, 28.9% [95% CI, 23.5%-35.1%]); nicotine patch plus nortriptyline (OR, 2.3 [95% CI, 1.3-4.2]; abstinence, 27.3% [95% CI, 17.2%-40.4%]); and nicotine patch plus nicotine inhaler (OR, 2.2 [95% CI, 1.2-3.6]; abstinence, 25.8% [95% CI, 17.4%-36.5%]).54,57 Toll-free telephone quit lines—now available for smokers in every state—increase quit rates in a range comparable with drug trials.64-66 Evidence for the efficacy of online quit programs, some but not all of which charge for their services, is also favorable, although less robust than for quit lines.67 Multi-impact systems such as those used by Kaiser Permanente of Northern California have successfully reduced smoking rates in their populations. Using a variety of interventions, including aggressive case-finding plus referral to cessation experts and quit lines, Kaiser was able to reduce its adult smoking prevalence from 12% to 9% in just 3 years.29 Several caveats apply to studies of smoking cessation. First, although smoking changes brain neurotransmitters and neuroplasticity—which should support categorizing it as a chronic disease—the therapies tested in most drug trials stop after 12 weeks.54 In contrast, treatment for other addictions, such as methadone maintenance for heroin addiction, is provided over a much longer duration. It is possible that longer treatment could yield higher cessation rates. For example, 52 weeks of nortriptyline plus extended counseling resulted in 50% cessation rates at the end of treatment.68 Second, smoking is a heterogeneous disease with differing degrees of use and addiction. It may be difficult to generalize results from 1 study to a given patient. Third, the published smoking cessation trials may be unduly optimistic for the average clinic population; quit rates in both the treatment and placebo groups of drug trials are higher than in the general population because of the high motivation of study participants and the higher quality, frequency, and duration of the counseling sessions. Spontaneous unaided quit rates are probably about 4%.54 Also, since the circumstances of each trial are different, one should be wary of making generalizations as to the relative efficacies of the different smoking cessation agents. Finally, drug trials typically exclude patients with mental illness, thereby eliminating a large number of smokers who may have lower cessation rates. Although smoking cessation rates are generally considered to be lower in persons with mental illness and/or substance abuse,48 there is abundant evidence that smokers with mental illness are able to quit. About 70% of smokers with mental illness want to quit,54,69-71 similar to the general population.72Quiz Ref IDFurthermore, a review of 24 published studies for all mental illnesses73 and a meta-analysis of 15 reports on patients with a history of major depression74 both concluded that rates of cessation among these patients were comparable with those of the general population. Specifically for major depression, studies have documented 12-month cessation rates of 22% using the combination of bupropion and counseling75 and as high as 32% for intensive counseling without pharmacotherapy.76 Therefore, clinicians should be encouraged to treat patients with depression and other forms of mental illness, such as Ms G, who want and are able to quit smoking. Unfortunately, clinicians, and physicians in particular, frequently do not incorporate smoking cessation into treatment for their patients with mental health diagnoses.77,78 A 2007 study conducted by the Association of American Medical Colleges/American Legacy Foundation compared physician practice patterns with respect to smoking cessation and found that while 89% of internists and 62% of psychiatrists ask their patients about smoking, only 19% and 14% arrange follow-up and 7% and 2%, respectively, refer patients to quit lines.79 Another study found that 60% of nurses surveyed believed that nicotine was the component in cigarettes that causes cancer and, therefore, were reluctant to recommend nicotine replacement therapy.80 In my experience, other clinicians have similar misunderstandings. What Are the Specific Treatment Concerns in Patients With Mental Illness? Standard cessation treatments of counseling and pharmacotherapy are appropriate in the mentally ill population.54 Bupropion should be considered for smokers with chronic depression, as it could have a double effect. Studies to date have shown higher cessation rates for varenicline plus counseling than for bupropion plus counseling,58,59,81,82 all but 1 of which82 have excluded patients with mental illness. There have been reports of suicidal ideation and worsening psychiatric symptoms in patients taking varenicline, including some who have continued to smoke.83-85 The FDA issued an alert and required Pfizer to provide a warning for varenicline (Chantix) and a change to its label and medication guide to state that “[s]ome patients have reported changes in behavior, agitation, depressed mood, suicidal thoughts or actions when attempting to quit smoking while taking Chantix or after stopping Chantix.” It states that patients experiencing such changes should stop taking Chantix and contact their physician. Of note, bupropion also carries such a warning (http://us.gsk.com/products/assets/us_zyban.pdf). The association between varenicline use and exacerbation of mental illness, the frequency of which has yet to be ascertained, must be balanced against the very high risk of continued smoking. Drug safety trials of varenicline among patients with mental illness are currently recruiting study participants (available at http://www.clinicaltrials.gov by using a search string for varenicline and schizophrenia or mental illness). Arguably, for a patient with acute psychiatric symptoms, cessation attempts should be deferred until they are stabilized,2 although much more research is needed on appropriate timing. Future Directions There are many unanswered questions about timing of cessation attempts for those with mental illness, long-term efficacy of treatments, and harm-reduction strategies that focus on decreasing the number of cigarettes smoked, rather than cessation. Perhaps most importantly, what will it take to command clinicians' attention to the devastating hidden epidemic in this population and undertake cessation efforts to stem it? Answers to these questions will come sooner if the mental health treatment community and the clients and families they represent advocate more strongly in the future than they have in the past. No other issue is as important for the long-term health and well-being of mentally ill patients. For individual patients, the question becomes how can we better motivate the mental health treatment community to give smoking and mental illness a higher priority?86 What is the role of non–mental health clinicians, such as internists and family physicians, in trying to help patients with mental illness stop smoking? As desirable as it might be to transform primary care and all other relevant clinicians—pulmonary specialists, diabetologists, cardiologists, obstetricians—into smoking cessation experts, it is an unrealistic goal. The achievable alternative, and one that I challenge and charge all clinicians with attaining, is to develop systems and resources to marshal essential nicotine cessation services. At a minimum, this should include referring the smoker to a quit line.77 No smoker should leave a physician's office without an offer of help to stop smoking. Recommendations for ms g Ms G should be congratulated for reducing her smoking level to 4 daily cigarettes. Now she should set a date to quit entirely. She is already taking 2 recommended smoking cessation drugs, bupropion and varenicline. There are as yet no studies assessing the efficacy of varenicline in combination with other cessation drugs, although anecdotally, such off-label use is not uncommon. The best cessation results come from a combination of counseling and drugs,54 and Ms G has indicated that she would welcome such counseling. If no counseling services are available at her institution, she should be directed to the free telephone quit line services (1-800-QUIT NOW). This system refers callers to their own state's quit line via this national routing number. Counseling should emphasize the continuing benefits of quitting as well as devise behavioral strategies to combat the urge to smoke. As to her concern about the duration of varenicline treatment, 1 published report has shown better cessation rates from 24-week therapy as opposed to the standard 12 weeks.81 The FDA has approved use of the drug for 6 months for those who initially responded to the drug. Another study of 251 patients randomized to varenicline and 126 to placebo demonstrated that patients can safely use the drug for up to 52 weeks.87 Approximately half of the participants (53.8% in the varenicline group and 46.8% in the placebo group) completed the study. There are no population-based data yet regarding safety or possible adverse effects from longer-term use. Of paramount importance to Ms G and other patients with mental illness is optimal treatment and careful monitoring of her psychotropic medications, as well as caution about symptoms of caffeine excess—both conditions of concern in the setting of decreased tobacco use. Her psychiatrist and internist should also be alert to the serious but rare complications that may be associated with varenicline use: suicidal ideation and mania. Should her current cessation program fail, Ms G should be offered another effort using both short- and longer-acting nicotine replacement therapy—with or without bupropion. Questions and discussion QUESTION: You spoke only briefly about weight gain, but in my practice, that is a tremendous issue for patients who contemplate quitting smoking. Are there any particular strategies for preventing weight gain in this scenario? DR SCHROEDER: Weight gain is a usual consequence of quitting smoking, whether one has mental illness or not, and whether or not cessation therapies are used in the quit attempt.54 The weight gain is said to average about 8 lb but it can be more. Many of the standard psychotropic medications are also associated with weight gain, so this can be an important compounding issue for many people with mental illness. Using bupropion in concert with nicotine replacement therapy, particularly the 4-mg nicotine gum and the lozenges, may delay weight gain, but it still occurs.54,57 It is probably best not to try to get people to change their diet at the same time they are stopping smoking, but once smoking is conquered, weight reduction strategies might be appropriate. It is also worth trying to couple cessation with increased exercise, instituting this in simple steps, such as advising patients to park at the far end of a parking lot instead of the closest spot. QUESTION: The Department of Veterans Affairs (VA) has been very aggressive in trying to reduce the rampant smoking throughout its facilities. Are there data on outcomes in terms of success or failure rates, changes in the costs of caring for the population, and rates of tobacco-associated diseases? DR SCHROEDER: The tobacco industry used to send cigarettes to soldiers in combat. During World War I, General Pershing said, “Send us two things to beat the Germans, bullets and cigarettes.” So we induced young men to smoke. The VA has recently taken on tobacco use as a major issue.88 The VA's facilities actually track cessation efforts as a medical quality indicator and rate their physicians accordingly.89 As a result, the VA does better than most systems in asking about smoking and urging cessation. Smoking cessation rates have not gone down as much as the VA would like, but they are declining.90 And VA facilities are now using telephone quit lines as a successful cessation option.91 Many veterans live at some distance from the local VA, so for them quit lines are a preferred option. I am not aware of whether there have been any documented declines in smoking-related illnesses among veterans as a result of these efforts. MS G’S PRIMARY CARE PHYSICIAN: Ms G is receiving ongoing mental health care. She is seeing a psychiatrist and a social worker regularly. When you refer to her needing “counseling,” do you mean, specifically, counseling directed at smoking cessation? DR SCHROEDER: Psychiatrists and psychiatric social workers are not limited to the typical brief encounter with patients that primary care physicians are. So they have more time to splice in smoking cessation counseling (cognitive and behavioral therapy) along with standard psychotherapy. But they typically don't do it. Why? First, they don't think of it because it is not yet part of the mental health treatment culture. Second, they don't feel comfortable doing it because they lack the training and expertise or, perhaps, because they are smokers themselves. Our center is attempting to make mental health clinicians more knowledgeable about smoking cessation strategies by providing them with a tailored version of the cessation curriculum Rx for Change, prepared by pharmacy faculty at the University of California, San Francisco (UCSF).57 This curriculum demonstrated significant changes in practice behavior of psychiatric residents with respect to undertaking cessation efforts, validated through chart review.92 We will help disseminate that curriculum so counselors will feel more comfortable with cessation efforts. QUESTION: Can you comment on the role of restrictions in public smoking in the decreasing prevalence of tobacco use? DR SCHROEDER: Credit for the decline in smoking prevalence over the past 4 decades generally focuses on a set of policy measures, especially tobacco taxes, clean indoor air laws, countermarketing, and smoking cessation efforts.93 Smoking is becoming denormalized and increasingly stigmatized.22,23 It is disappointing that the prevalence of smoking has plateaued recently, after years of progressive steady decline. But the Centers for Disease Control and Prevention recently reported that smoking prevalence for the first 6 months of 2007 was at a modern age-adjusted low of 19.8%.11 There are tremendous variations in population smoking prevalence. Smoking is much more prevalent in southern states, among the poor, and in people with low educational attainment.77 A recent study showed that patients resume smoking after discharge from mental hospitals but also commented that they were not given adequate cessation assistance.94 QUESTION: If the National Institutes of Health (NIH) is designed to improve the health of Americans and if the biggest preventable problem is tobacco, do you think the NIH ought to change the way it is organized? DR SCHROEDER: The reality today is that the NIH is more concerned with basic mechanisms of disease and molecular biology than in researching the efficacy of various clinical strategies. The latter role tends to be financed by the pharmaceutical industry, but since so many of the evidence-based cessation techniques are either off-patent drugs or counseling, there is little incentive for industry to study these or to analyze the efficacy of various combinations. So, there needs to be pressure on the NIH to expand its research agenda on smoking cessation. But pressures of that sort require well-organized and passionate advocacy groups of patients, families, and clinicians. Because of the stigma surrounding smoking, there are no such advocacy groups. It may be up to the medical and public health community to exert that pressure.1 Back to top Article Information Corresponding Author: Steven A. Schroeder, MD, University of California, San Francisco, 3333 California St, Ste 430, San Francisco, CA 94143-1211 (schroeder@medicine.ucsf.edu). Financial Disclosures: None reported. Funding/Support: Dr Schroeder is funded by the Robert Wood Johnson and American Legacy Foundations. Role of the Sponsor: The funding organizations did not participate in the collection, analysis, and interpretation of the data or in the preparation, review, or approval of the manuscript. Additional Contributions: We thank the patient for sharing her story and for providing permission to publish it. Dr Schroeder is indebted to Erica Solway, MSW, MPH, UCSF, for assistance, to Neal Benowitz, MD, UCSF, and Doug Ziedonis, MD, University of Massachusetts, for comments on an earlier version of the manuscript, to Karen Hudmon, DrPH, PRH, MS, Purdue University, Lisa Kroon, PharmD, CDE, UCSF, and Robin Correlli, PharmD, UCSF, for their superb efforts in creating Rx for Change, and to Amy J. Markowitz, JD, for editorial assistance. Ms Markowitz was compensated for her contributions. This conference took place at the Medicine Grand Rounds at Beth Israel Deaconess Medical Center, Boston, Massachusetts, on December 13, 2007. Clinical Crossroads at Beth Israel Deaconess Medical Center is produced and edited by Risa B. Burns, MD, series editor; Tom Delbanco, MD, Howard Libman, MD, Eileen E. Reynolds, MD, Amy N. Ship, MD, and Anjala V. Tess, MD. References 1. Schroeder SA. A hidden epidemic. Washington Post. November 18, 2007:B07. http://www.washingtonpost.com/wp-dyn/content/article/2007/11/16/AR2007111601618.html. Accessed January 15, 2009 2. Ziedonis DM, Williams JM, Steinberg ML, et al. Addressing tobacco dependence among veterans with a psychiatric disorder: a neglected epidemic of major clinical and public health concern. In: Isaacs SL, Schroeder SA, Simon JA, eds. VA in the Vanguard: Building on Success in Smoking Cessation. Washington, DC: Department of Veterans Affairs; 2005 3. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential lives lost, and causes of death among public health mental clients in eight states. Prev Chronic Dis. 2006;3(2). http://cdc.gov/pcd/issues/2006/Apr/05_0180.htm. Accessed November 1, 2008 4. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76(2-3):135-15715949648PubMedGoogle ScholarCrossref 5. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. JAMA. 2000;284(20):2606-261011086367PubMedGoogle ScholarCrossref 6. Kalman D, Morissette SB, George TP. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict. 2005;14(2):106-12316019961PubMedGoogle ScholarCrossref 7. Kollins SH, McClernon FJ, Fuemmeler BF. Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults. Arch Gen Psychiatry. 2005;62(10):1142-114716203959PubMedGoogle ScholarCrossref 8. Beckham JC, Roodman AA, Shipley RH, et al. Smoking in Vietnam combat veterans with post-traumatic stress disorder. J Trauma Stress. 1995;8(3):461-4727582610PubMedGoogle ScholarCrossref 9. Breslau N, Davis GC, Schultz LR. Posttraumatic stress disorder and the incidence of nicotine, alcohol, and other drug disorders in persons who have experienced trauma. Arch Gen Psychiatry. 2003;60(3):289-29412622662PubMedGoogle ScholarCrossref 10. Grant BF, Hasin DS, Chou SP, Stinson FS, Dawson DA. Nicotine dependence and psychiatric disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61(11):1107-111515520358PubMedGoogle ScholarCrossref 11. National Center for Health Statistics. Early release of selected estimates based on data from the January-June 2007 National Health Interview Study. http://www.cdc.gov/nchs/about/major/nhis/about200712.htm. Accessed November 1, 2008 12. Kandel DB, Huang FY, Davies M. Comorbidity between patterns of substance use dependence and psychiatric syndromes. Drug Alcohol Depend. 2001;64(2):233-24111543993PubMedGoogle ScholarCrossref 13. Satcher DS. Executive summary: a report of the Surgeon General on mental health. Public Health Rep. 2000;115(1):89-10110968589PubMedGoogle ScholarCrossref 14. D’Mello DA, Bandlamudi GR, Colenda CC. Nicotine replacement methods on a psychiatric unit. Am J Drug Alcohol Abuse. 2001;27(3):525-52911506266PubMedGoogle ScholarCrossref 15. Morris CD, Giese AA, Turnbull JJ, Dickinson M, Johnson-Nagel N. Predictors of tobacco use among persons with mental illnesses in a statewide population. Psychiatr Serv. 2006;57(7):1035-103816816291PubMedGoogle ScholarCrossref 16. Williams JM, Ziedonis D. Addressing tobacco among individuals with a mental illness or an addiction. Addict Behav. 2004;29(6):1067-108315236808PubMedGoogle ScholarCrossref 17. Mauer B. Morbidity and mortality in people with serious mental illness. In: Parks J, Svendsen D, Singer P, Foti ME, eds. Technical Report 13. Alexandria, VA: National Association of State Mental Health Program Directors Council; 2006 18. Hurt RD, Offord KP, Croghan IT, et al. Mortality following inpatient addictions treatment: role of tobacco use in a community-based cohort. JAMA. 1996;275(14):1097-11038601929PubMedGoogle ScholarCrossref 19. Steinberg ML, Williams JM, Ziedonis DM. Financial implications of cigarette smoking among individuals with schizophrenia. Tob Control. 2004;13(2):20615175544PubMedGoogle ScholarCrossref 20. Mechanic D, Blider S, McAlpine DD. Employing persons with serious mental illness. Health Aff (Millwood). 2002;21(5):242-25312224889PubMedGoogle ScholarCrossref 21. Chapman S, Freeman B. Markers of the denormalisation of smoking and the tobacco industry. Tob Control. 2008;17(1):25-3118218803PubMedGoogle ScholarCrossref 22. Christakis NA, Fowler JH. The collective dynamics of smoking in a large social network. N Engl J Med. 2008;358(21):2249-225818499567PubMedGoogle ScholarCrossref 23. Schroeder S. Stranded in the periphery-the increasing marginalization of smokers. N Engl J Med. 2008;358(21):2284-228618499574PubMedGoogle ScholarCrossref 24. Williams JM. Eliminating tobacco use in mental health facilities: patients' rights, public health, and policy issues. JAMA. 2008;299(5):571-57318252888PubMedGoogle ScholarCrossref 25. Reilly P, Murphy L, Alderton D. Challenging the smoking culture within a mental health service supportively. Int J Ment Health Nurs. 2006;15(4):272-27817064324PubMedGoogle ScholarCrossref 26. Burke M. Technical report on smoking policy and treatment in state operated psychiatric facilities. In: Parks J, Jewell P, eds. Technical Report 12. Alexandria, VA: National Association of State Mental Health Program Directors Medical Directors Council; 2006 27. Monihan KM, Schacht LM, Parks J. A Comparative Analysis of Smoking Policies and Practices Among State Psychiatric Hospitals. http://www.nri-inc.org/reports_pubs/2006/SmokingPoliciesProceduresReport2006.pdf. Accessed December 11, 2008 28. Prochaska JJ, Hall SM, Bero LA. Tobacco use among individuals with schizophrenia: what role has the tobacco industry played? Schizophr Bull. 2008;34(3):555-56717984298PubMedGoogle ScholarCrossref 29. Smoking Cessation Leadership Center home page. http://smokingcessationleadership.ucsf.edu. Accessed November 2, 2008 30. Benowitz NL. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther. 2008;83(4):531-54118305452PubMedGoogle ScholarCrossref 31. Benowitz NL. Cigarette smoking and nicotine addiction. Med Clin North Am. 1992;76(2):415-4371548969PubMedGoogle Scholar 32. Leshner AI. Drug abuse and addiction are biomedical problems. Hosp Pract. April 1997;2-4Special reportGoogle Scholar 33. Perry DC, Davila-Garcia MI, Stockmeier CA, Kellar KJ. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J Pharmacol Exp Ther. 1999;289(3):1545-155210336551PubMedGoogle Scholar 34. McCaffery JM, Niaura R, Swan GE, Carmelli D. A study of depressive symptoms and smoking behavior in adult male twins from the NHLBI twin study. Nicotine Tob Res. 2003;5(1):77-8312745509PubMedGoogle ScholarCrossref 35. Dierker LC, Avenevoli S, Merikangas KR, Flaherty BP, Stolar M. Association between psychiatric disorders and the progression of tobacco use behaviors. J Am Acad Child Adolesc Psychiatry. 2001;40(10):1159-116711589528PubMedGoogle ScholarCrossref 36. Lyons M, Hitsman B, Xian H, et al. A twin study of smoking, nicotine dependence, and major depression in men. Nicotine Tob Res. 2008;10(1):97-10818188750PubMedGoogle ScholarCrossref 37. Lerman C, Caporaso N, Main D, et al. Depression and self-medication with nicotine: the modifying influence of the dopamine D4 receptor gene. Health Psychol. 1998;17(1):56-629459071PubMedGoogle ScholarCrossref 38. Audrain-McGovern J, Lerman C, Wileyto EP, Rodriguez D, Shields PG. Interacting effects of genetic predisposition and depression on adolescent smoking progression. Am J Psychiatry. 2004;161(7):1224-123015229055PubMedGoogle ScholarCrossref 39. Johnson EO, Breslau N. Is the association of smoking and depression a recent phenomenon? Nicotine Tob Res. 2006;8(2):257-26216766418PubMedGoogle ScholarCrossref 40. Kassel JD, Stroud LR, Paronis CA. Smoking, stress, and negative affect: correlation, causation, and context across stages of smoking. Psychol Bull. 2003;129(2):270-30412696841PubMedGoogle ScholarCrossref 41. Ziedonis DM, Kosten TR, Glazer WM, Frances RJ. Nicotine dependence and schizophrenia. Hosp Community Psychiatry. 1994;45(3):204-2067910577PubMedGoogle Scholar 42. Fowler JS, Volkow ND, Wang GJ, et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature. 1996;379(6567):733-7368602220PubMedGoogle ScholarCrossref 43. Hughes JR. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res. 2007;9(3):315-32717365764PubMedGoogle ScholarCrossref 44. Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm. 2007;64(18):1917-192117823102PubMedGoogle ScholarCrossref 45. Sánchez-Villegas A, Serrano-Martinez M, Alonso A, de Irala J, Tortosa A, Martinez-Gonzalez MA. Role of tobacco use on the incidence of depression in the SUN cohort study. Med Clin (Barc). 2008;130(11):405-40918394364PubMedGoogle ScholarCrossref 46. Paperwalla KN, Levin TT, Weiner J, Saravay SM. Smoking and depression. Med Clin North Am. 2004;88(6):1483-1494, x-xi15464109PubMedGoogle ScholarCrossref 47. Glassman AH, Covey LS, Stetner F, Rivelli S. Smoking cessation and the course of major depression: a follow-up study. Lancet. 2001;357(9272):1929-193211425414PubMedGoogle ScholarCrossref 48. Glassman AH. Cigarette smoking: implications for psychiatric illness. Am J Psychiatry. 1993;150(4):546-5538465868PubMedGoogle Scholar 49. Tsoh JY, Humfleet GL, Munoz RF, Reus VI, Hartz DT, Hall SM. Development of major depression after treatment for smoking cessation. Am J Psychiatry. 2000;157(3):368-37410698811PubMedGoogle ScholarCrossref 50. Prochaska JJ, Hall SM, Tsoh JY, et al. Treating tobacco dependence in clinically depressed smokers: effect of smoking cessation on mental health functioning. Am J Public Health. 2008;98(3):446-44817600251PubMedGoogle ScholarCrossref 51. McNally L, Oyefeso A, Annan J, et al. A survey of staff attitudes to smoking-related policy and intervention in psychiatric and general health care settings. J Public Health (Oxf). 2006;28(3):192-19616809790PubMedGoogle ScholarCrossref 52. Levin A. State hospitals struggle to give up smoking. Psychiatr News. 2007;42:4Google Scholar 53. Apollonio DE, Malone RE. Marketing to the marginalised: tobacco industry targeting of the homeless and mentally ill. Tob Control. 2005;14(6):409-41516319365PubMedGoogle ScholarCrossref 54. Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update Practice Guideline. Rockville, MD: Public Health Service; 2008 55. Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev. 2005;(2):CD00100715846610PubMedGoogle Scholar 56. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2008;(1):CD00014618253970PubMedGoogle Scholar 57. Regents of the University of California, University of Southern California, and Western University of Health Sciences. Rx for Change: Clinician-Assisted Tobacco Cessation. http://rxforchange.ucsf.edu. Accessed November 2, 2008 58. Gonzales D, Rennard SI, Nides M, et al; Varenicline Phase 3 Study Group. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47-5516820546PubMedGoogle ScholarCrossref 59. Jorenby DE, Hays JT, Rigotti NA, et al; Varenicline Phase 3 Study Group. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):56-6316820547PubMedGoogle ScholarCrossref 60. Schroeder SA, Sox HC. Trials that matter: varenicline: a designer drug to help smokers quit. Ann Intern Med. 2006;145(10):784-78517116925PubMedGoogle ScholarCrossref 61. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007;(1):CD00003117253443PubMedGoogle Scholar 62. Killen JD, Fortmann SP, Schatzberg AF, et al. Nicotine patch and paroxetine for smoking cessation. J Consult Clin Psychol. 2000;68(5):883-88911068974PubMedGoogle ScholarCrossref 63. David S, Lancaster T, Stead LF, Evins AE. Opioid antagonists for smoking cessation. Cochrane Database Syst Rev. 2006;(4):CD00308617054160PubMedGoogle Scholar 64. Zhu SH, Anderson CM, Tedeschi GJ, et al. Evidence of real-world effectiveness of a telephone quitline for smokers. N Engl J Med. 2002;347(14):1087-109312362011PubMedGoogle ScholarCrossref 65. Zhu SH, Anderson CM. Tobacco quitlines: where they’ve been and where they're going. In: Isaacs SL, Schroeder SA, Simon JA, eds. VA in the Vanguard: Building Success in Smoking Cessation. Washington, DC: Department of Veterans Affairs; 2005:207-217 66. Ossip-Klein DJ, McIntosh S. Quitlines in North America: evidence base and applications. Am J Med Sci. 2003;326(4):201-20514557735PubMedGoogle ScholarCrossref 67. Muñoz RF, Lenert LL, Delucchi K, et al. Toward evidence-based internet interventions: a Spanish/English Web site for international smoking cessation trials. Nicotine Tob Res. 2006;8(1):77-8716497602PubMedGoogle ScholarCrossref 68. Hall SM, Humfleet GL, Reus VI, Munoz RF, Cullen J. Extended nortriptyline and psychological treatment for cigarette smoking. Am J Psychiatry. 2004;161(11):2100-210715514412PubMedGoogle ScholarCrossref 69. Prochaska JJ, Rossi JS, Redding CA, et al. Depressed smokers and stage of change: implications for treatment interventions. Drug Alcohol Depend. 2004;76(2):143-15115488338PubMedGoogle ScholarCrossref 70. Lucksted A, McGuire C, Postrado L, Kreyenbuhl J, Dixon LB. Specifying cigarette smoking and quitting among people with serious mental illness. Am J Addict. 2004;13(2):128-13815204664PubMedGoogle ScholarCrossref 71. Tsoh JY, Hall SM. Depression and smoking: from the transtheoretical model of change perspective. Addict Behav. 2004;29(4):801-80515135563PubMedGoogle ScholarCrossref 72. Centers for Disease Control and Prevention. Cigarette smoking among adults—United States, 2000. MMWR Morb Mortal Wkly Rep. 2002;51(29):642-64512186222PubMedGoogle Scholar 73. El-Guebaly N, Cathcart J, Currie S, Brown D, Gloster S. Smoking cessation approaches for persons with mental illness or addictive disorders. Psychiatr Serv. 2002;53(9):1166-117012221317PubMedGoogle ScholarCrossref 74. Hitsman B, Borrelli B, McChargue DE, Spring B, Niaura R. History of depression and smoking cessation outcome: a meta-analysis. J Consult Clin Psychol. 2003;71(4):657-66312924670PubMedGoogle ScholarCrossref 75. Brown RA, Niaura R, Lloyd-Richardson EE, et al. Bupropion and cognitive-behavioral treatment for depression in smoking cessation. Nicotine Tob Res. 2007;9(7):721-73017577801PubMedGoogle ScholarCrossref 76. Brown RA, Kahler CW, Niaura R, et al. Cognitive-behavioral treatment for depression in smoking cessation. J Consult Clin Psychol. 2001;69(3):471-48011495176PubMedGoogle ScholarCrossref 77. Schroeder SA. What to do with a patient who smokes. JAMA. 2005;294(4):482-48716046655PubMedGoogle ScholarCrossref 78. Thorndike AN, Stafford RS, Rigotti NA. US physicians' treatment of smoking in outpatients with psychiatric diagnoses. Nicotine Tob Res. 2001;3(1):85-9111260815PubMedGoogle ScholarCrossref 79. American Association of Medical Colleges. Physician Behavior and Practice Patterns Related to Smoking Cessations. http://www.aamc.org/workforce/smoking-cessation-full.pdf. Accessed November 2, 2008 80. Borrelli B, Novak SP. Nurses' knowledge about the risk of light cigarettes and other tobacco “harm reduction” strategies. Nicotine Tob Res. 2007;9(6):653-66117558822PubMedGoogle ScholarCrossref 81. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR.Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):64-7116820548PubMedGoogle ScholarCrossref 82. Stapleton JA, Watson L, Spirling LI, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction. 2008;103(1):146-15418028247PubMedGoogle ScholarCrossref 83. Kohen I, Kremen N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry. 2007;164(8):1269-127017671294PubMedGoogle ScholarCrossref 84. Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry. 2007;164(8):126917671295PubMedGoogle ScholarCrossref 85. Institute for Safe Medication Practices. Strong Safety Signal Seen for New Varenicline Risks. http://www.ismp.org/docs/vareniclinestudy.asp. Accessed November 14, 2008 86. Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA. 2007;298(15):1794-179617940236PubMedGoogle ScholarCrossref 87. Williams KE, Reeves KR, Billing CB Jr, Pennington AM, Gong J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin. 2007;23(4):793-80117407636PubMedGoogle ScholarCrossref 88. Isaacs SL, ed, Schroeder SA, ed, Simon JA, ed. VA in the Vanguard: Building on Success in Smoking Cessation. http://smokingcessationleadership.ucsf.edu/AboutSCLC_vanguard.html. Accessed November 2, 2008 89. Hamlett-Berry K. Smoking cessation policy in the VA health care system: where have we been and where are we going? In: Isaacs SL, Schroeder SA, Simon JA, eds. VA in the Vanguard: Building on Success in Smoking Cessation. Washington, DC: Department of Veterans Affairs; 2005:7-29 90. Saxon AJ. Tobacco use and mental illness: neuropsychiatric links and mechanisms. In: A Preceptor Training Program to Improve Delivery of Tobacco Cessation Treatment for Veterans With Mental Disorders. Washington, DC: Department of Veterans Affairs; 2006:13-14 91. Joseph AM, An LC. Telephone care for smoking cessation in the department of Veterans Affairs. In: Isaacs SL, Schroeder SA, Simon JA, eds. VA in the Vanguard: Building on Success in Smoking Cessation. Washington, DC: Department of Veterans Affairs; 2005:207-217 92. Prochaska JJ, Fromont SC, Leed D, et al. Evaluation of an evidence-based tobacco treatment curriculum for psychiatry residency training programs. Acad PsychiatryIn pressGoogle Scholar 93. Warner KE. Tobacco policy research: insights and contributions to public health policy. In: Warner KE, ed. Tobacco Control Policy. San Francisco, CA: Jossey-Bass; 2007:3-86 94. Prochaska JJ, Fletcher L, Hall SE, Hall SM. Return to smoking following a smoke-free psychiatric hospitalization. Am J Addict. 2006;15(1):15-2216449089PubMedGoogle ScholarCrossref

Journal

JAMAAmerican Medical Association

Published: Feb 4, 2009

Keywords: smoking,mental disorders,cigarettes,bipolar disorder,counseling,substance abuse,pharmacotherapy,smoking cessation,mental health,death

There are no references for this article.